Podcasts about nih

Synopsis: Host Rahul Chaturvedi sits down with Geoffrey Duyk, Chief Executive Officer of Grove Biopharma, for a wide-ranging conversation on navigating today's biotech macro headwinds and building companies that can translate breakthrough science into real patient impact. Dr. Duyk traces his journey from Harvard/Millennium/Exelixis operator to TPG investor and back to company creation, explaining how board dynamics, capital cycles, and policy shifts shape execution. They dig into why this cycle feels uniquely tough—patent cliffs, reimbursement uncertainty, NIH pressures—and who funds innovation in the meantime. Duyk outlines root causes of R&D inefficiency (misaligned capital vs. 20-year timelines, shaky preclinical predictability, costly trials, underused real-world data) and makes the case for rebuilding public trust and STEM education. Then, a deep dive on Grove Biopharma: precision polymer science that creates antibody-like, fully synthetic, cell-permeable protein mimetics to tackle historically “intractable” intracellular protein–protein interactions. Duyk shares design principles, why modular/orthogonal chemistry matters, predictable pharmacology, and lessons from fundraising and board management—plus why he's helping grow a Chicago-centered biotech ecosystem. Biography: Geoffrey M. Duyk, M.D., Ph.D. is the Chief Executive Officer of Grove Biopharma. Dr. Duyk has spent 30 years in the biotechnology industry as an entrepreneur, executive, and investor. Most recently, he was the Managing Partner at Circularis Partners, an investment firm he co-founded, focused on advancing the circular economy and promoting sustainability. Prior to that, Dr. Duyk was Managing Director and Partner at TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology. Before joining TPG, Dr. Duyk served as a board member and President of R&D at Exelixis and was one of the founding scientific staff members at Millennium Pharmaceuticals, where he served as Vice President of Genomics. Earlier in his career, Dr. Duyk was an Assistant Professor in the Department of Genetics at Harvard Medical School (HMS) and an Assistant Investigator at the Howard Hughes Medical Institute (HHMI). While at HMS, he served as a co–principal investigator in the Cooperative Human Linkage Center, which was funded by the National Institutes of Health (NIH). Dr. Duyk is a trustee of Case Western Reserve University, where he serves on the executive committee. He previously served on the Board of Trustees of Wesleyan University and the Board of Directors of the Moffitt Cancer Center. He currently serves on the IR&E (Institutional Research and Evaluation) Committee at Moffitt, a key component of its External Advisory Committee (EAC). He was also a member of the Board of Directors of the American Society of Human Genetics (ASHG), and served as its treasurer. He is a member of the Life Sciences Advisory Board at Innovatus Capital Partners and the Scientific Advisory Board (SAB) for Lawrence Berkeley National Laboratory (DOE). Dr. Duyk previously served on the board of the Jackson Laboratory and on numerous NIH advisory committees. He is currently a Senior Advisor at Qiming Venture Partners (USA) and serves on the boards of Enno DC, Oobli, and Melanyze Dr. Duyk earned both his M.D. and Ph.D. from Case Western Reserve University and completed his medical and fellowship training at the University of California, San Francisco (UCSF). While at UCSF, he was a Lucille P. Markey Fellow and an HHMI postdoctoral fellow. He is a fellow of the American Association for the Advancement of Science.

Emily is an Assistant Professor at MDI Biological Laboratory where she studies neurodegenerative disease-associated genes using super-resolution imaging of living, adult worms. Emily earned her Ph.D. at the University of Maine while embedded in the Jackson Laboratory and during her post-doc at MDI Bio Lab, she was recognized by the National Institutes of Health as an “Outstanding Scholar in Neuroscience”.This conversation was recorded in September 2025. ~~~~~The Maine Science Podcast is a production of the Maine Discovery Museum. It is recorded at Discovery Studios, at the Maine Discovery Museum, in Bangor, ME. The Maine Science Podcast is hosted and executive produced by Kate Dickerson; edited and produced by Scott Loiselle. The Discover Maine theme was composed and performed by Nick Parker. To support our work: https://www.mainediscoverymuseum.org/donate. Find us online:Maine Discovery MuseumMaine Discovery Museum on social media: Facebook Instagram LinkedIn Bluesky Maine Science Festival on social media: Facebook Instagram LinkedInMaine Science Podcast on social media: Facebook Instagram © 2025 Maine Discovery Museum

Vi har visst lite om høyintensiv trening under graviditet - men nå vet vi endeleg mer! I denne episoden av NIH-podden får du høre om fersk forskning fra Strong Mama-prosjektet – der 60 topputøvere og svært aktive kvinner ble testet under graviditet for å finne ut hvordan fosteret påvirkes av høyintensiv trening. Gjester i studio er doktorgradsstipendiat Emilie Mass Dalhaug og Lene Haakstad, professor ved NIH. Du får også møte Melina Meyer Magulas, skiløper og løper, som selv deltok i studien, og deler sine erfaringer med å trene på høy puls i tredje trimester.

I am thrilled to have Gary Taubes back on the show today. (He was with me before on episode 137. Gary is an investigative science and health journalist whose work has been pivotal in catalyzing the low-carb keto movement. He has written many books, including his most recent, Rethinking Diabetes, and his articles are in many of the best anthologies. He has also received many science awards. Today's discussion is particularly significant, given the recent report from the American Diabetes Association revealing that the annual cost of diabetes in the United States reached a staggering $412.9 billion in 2022, with individuals diagnosed with diabetes now representing one in every four dollars spent on healthcare.  In our discussion today, we dive into the history of diabetes, pertinent statistics, the prevailing standard of care, and the transformative influence of insulin on diabetes management and reactive hypoglycemia. Gary provides insights into his reactions to GLP ones, the integration of medical and nutrition science into the medical field, and the influence of organizations such as the American Diabetes Association, AHA, USDA, and NIH. Our discussion also extends to the effects of pharmaceuticals, the shortcomings in our approach to diabetes management and existing models, and the challenge the low-carb community faces. Stay tuned for today's eye-opening conversation, where we shed light on the complexities surrounding diabetes care, explaining how simple lifestyle changes can tremendously improve quality of life. IN THIS EPISODE YOU WILL LEARN: Rethinking Diabetes is a groundbreaking exploration of diabetes diagnosis, management, and treatment Gary discusses the evolution of evidence-based medicine Why the traditional medical approach to treating diabetes is inadequate How the guidelines of the American Diabetes Association were based on outdated assumptions  How medical treatments compare with lifestyle changes for managing diabetes Controversies surrounding how the pharmaceutical industry has influenced the way medical associations have shaped their diabetes management policies How medical guidelines and dietary advice have evolved What constitutes a healthy diet? How patients often have trouble following diet recommendations, despite their best intentions Is obesity a hormonal disorder or caused by overeating?  Connect with Cynthia Thurlow Follow on X, ⁠Instagram⁠ & ⁠LinkedIn⁠ Check out Cynthia's ⁠website⁠ Submit your questions to support@cynthiathurlow.com Connect with Gary Taubes On his ⁠website⁠ X ⁠Facebook⁠ Previous Episode Mentioned ⁠Ep. 137 – High Blood Sugar Levels And Its Long-Term Damage with Gary Taubes⁠ Book Mentioned: Rethinking Diabetes: What Science Reveals About Diet, Insulin, and Successful Treatments is available from most bookstores or on ⁠Amazon⁠.

In this episode of the Metabolic Mind podcast, Dr. Bret Scher speaks with L.J. Amaral, a registered dietitian, certified in nutrition oncology, and PhD student researcher at Cedars-Sinai, about where ketogenic therapy may fit into cancer care. Together they emphasize a crucial point: in oncology, we're not just treating the tumor, we're treating the whole person. The quality of life, physical strength, and day-to-day function of patients matter in prognosis.L.J. covers:How shifting fuel toward ketones may influence metabolism, inflammation, fatigue, and even muscle preservation during treatment.Why many tumors crave glucose, and why that matters for dietary strategies.The potential of ketogenic therapy used alongside standard of care (surgery/chemo/radiation), with early signals around feasibility, daily living, and patient well-being.The real-world nuance of responders vs. non-responders, and why personalized coaching is key.How some patients pair fasting windows with treatment, and the practical safeguards to consider.What's next: details on an NIH-funded, multi-center phase 2 trial comparing a ketogenic approach to an American Cancer Society–style diet.Ketogenic therapy in oncology is early but advancing. If you're curious about science-backed nutrition strategies that support both treatment and daily life, this conversation is for you.

Piše Jože Štucin, bereta Igor Velše in Mateja Perpar. Roman Samo seks se napaja pri izviru erotike, seksualnosti, a govori in reflektira o vsem mogočem. Pisateljica Erika Johnson Debeljak je vanj postavila primarne reči, vse pa je zgradila na bivanjski substanci razmnoževalnega akta, ki opredeljuje življenje, ga celo poraja, a če smo pri tej oznaki vsaj malo previdni, skozi branje seks postaja vedno bolj muzikalen, večglasen, kot kakšen krasen zborovski seks-tet, proti koncu knjige pa se besedi pridruži še "pripomenka" sekstant, orodje, ki nas vodi po svetu, nam kaže strani neba in nam pomaga živeti. Knjiga je, to nam kmalu postane jasno, roman, ki miselno in vsebinsko plahuta po civilizaciji, obdeluje vse mogoče teme, s seksom pa se ukvarja sporadično, kot bi brskali po netu za pornografskimi vsebinami in ob slikah imeli čisto druge misli v glavi. Libido je širok pojem. Mogoče se res začne z vonjavami izpod pazduhe, konča pa se gotovo v abstraktnih parfumih, ki segajo do neba. Tudi eros je delikatna beseda s številnimi vsebinami in pomeni. Če smo jezikovno dosledni, je pri starih Grkih to bog ljubezni, poželenja in spolne privlačnosti, Rimljani so ga preimenovali v Amorja, vendar ni, da bi človek preveč razglabljal – seks, ki nekako krmari knjigo, je pač tista elementarna prvina, nemara goli gon, nagon in sla, ki vse pogojuje. Erosa ni brez seksa, če bi hoteli biti pragmatični, platonovski verziji navkljub, kjer oznaka pomeni višjo, duhovno obliko ljubezni, silo, ki človeka vodi k lepoti in modrosti. Ergo, na spolzkih tleh smo, ko zaidemo v ta arhetip, v ta summus vseh človekovih stremljenj in dejanj, ki ga je med prvimi iz mita izluščil Sigmund Freud in mu nadel uzde, ki konja vodijo, gonijo in krotijo ... Vsaj mislimo, da je tako. Glede na tematiko ne preseneča, da pisateljica začenja roman z Meduzo. Za razumevanje branja je vendarle treba vedeti, kaj ta starogrški mit pomeni in v kakšne variabilne oblike se je skozi zgodovino modificiral. Meduza, ena od treh Gorgon, je bila smrtnica. Sprva ni bila pošast, temveč lepa deklica, ki je služila kot svečenica v Ateninem templju. To, porečemo, je bilo lepo delo, no, se pa stvari zapletejo, ko jo je bog morja Pozejdon zapeljal, mogoče celo posilil. Atena se je razjezila – kako domače! – ne na Pozejdona, temveč na Meduzo in jo spremenila v pošast z lasmi iz kač, in vsak, ki bi jo pogledal, bi se spremenil v kamen. Meduza v tem romanu je čista metafora, je samo namig v smeri mitologije, v tiste plasti literature, kjer se kopičijo arhetipi, pravzgibi, osnovne strasti, nagon po življenju. Glavna protagonostka v knjigi je vendarle sodobna ženska, ki se sooča s staranjem, ki počasi čuti v sebi smrtno sapo, konec "mita", in se zaradi tega nenadejanega položaja, ko se vse sanje po zakonih narave spreminjajo v moro, začne ukvarjati sama s sabo na zanimiv način. Pisateljica pravi, da gre za "protiljubezensko zgodbo". Glavna oseba v knjigi je Ona v tretji osebi: "Njo svet vidi, toda le, če se tako odloči, in pri mojih letih – kajti če uporabim kliše, moja najboljša leta so mimo, sem ženska na napačni strani šestdesetega - se raje odloča za ne. Se pravi, je nevidna, prozorna, skoraj neobsotoječa." Slednje, o nevidnosti, je kasneje lepo razdelano. Staranje pomeni počasno izginjanje iz vidnega polja sveta. Nihče ne opazi starca, ni zanimiv, nima perspektive, ni atrakcija za oko. To pa je lahko, tudi pravi avtorica, celo koristno, saj kot nevidnež, kot nihče, lahko opazuješ življenje brez interakcije, brez refleksij in povratnih impulzov; resnica postaja jasna in popolnoma čista ter – enosmerna. Tole je nekakšen pritajeni kredo v knjigi, nekakšen potisk za bralca, ki si o staranju ne želi vedeti veliko ali celo nič, a ga te uvodne teze prepričajo, da bere naprej in proti koncu že hlasta po zgodbi. Pisateljica se je spretno izognila lamentacijam vobče, jamranju in strahu pred smrtjo na način, ki preferira mladost, živost in erotično razburljivost. Še zadnjič postaja deklica s sanjami, zakaj pa ne?, kdo nam določa, kdaj je konec strasti, hrepenenja, ljubezi in seksa. Patriarhat, ta kumulus naše civilzacije, nam govori eno, starejša gospa, pa gre po svoje, suvereno in odločno. In naenkrat smo na drugem polu iste premice življenjske črte, ki jo tokrat riše Tinder, in se vprašamo: Kaj ti je, babica? Zakaj so tvoje želje tako velike? Zakaj še hrepeniš po moškem, ker imaš že suha usta od skrbi in peze življenja? Kje so tvoje meje? Zakaj si še polna sle in upanja? Krasna prekucija, v romanesknem in vsebinskem smislu, preskok na premici življenja, ko se proti koncu oziramo nazaj in živimo naprej, avtorica pa nonšalantno ošvrkne svet, ki ga krojijo moški, tudi možače in ponižne ženske, in v prvi plan postavi svojo vizijo svobode, osvobojenosti, nekakšne enakopravnosti in enakovrednosti. Hecno je, da za svoj boj v roke vzame moško orožje, seks, uzi, ki ponavadi kosi po ženskih sužnjah in zadovoljuje samo moški del populacije. Sicer je preprosto, pisateljica že uvodoma namigne, "da so dogodki zgolj naključni, a ne bi imela nič proti, če bi si ji res zgodili," saj se v krizi poznih srednjih let, če pomislimo, da je premagala že vsa "mlada leta" in se sooča s starostjo, odloči na svoj računalnik naložiti program za stike, znameniti Tinder in nadaljevati "mladost". Kratek rezime romana, ki je poln duhovitih izpeljav, iskrivih razmislekov o položaju ženske v našem času, pa tudi na splošno, skratka o dominaciji patriarhata, pa o staranju, predvsem v povezavi s predsodkom, da ženske v zrelih letih (tu je eksplicitno mišljeno po menopavzi, v času sušenja kože in povešanja seksualnih kazalnikov) po nekakšni nazadnjaški tezi ne morejo in ne smejo imeti več spolnih želja. Avtorica se odloči pokazati nove poti, povzdigniti zgodbo do ekstremov, ko se srečata pornografija in primarna sla, živa želja po seksu, še pretkana z ljubezenskimi občutki in nagonom, ki prek suhega užitka »male smrti« vodi v dokončno odmrtje. Intrigantski roman brez primere, voaerje bo vlekel v podrobnosti, emanicipirane bralke bo celo odvračal od konzumacije, sploh, ker avtorica brez težav preklaplja v svet moških pornografskih fantazij; za nekoga, ki ga zamika Erica Johnoson Debeljak, imenitna avtorica, ki se je naselila v naši kulturi in ima častitljiv renome, pa bo branje lep doživljaj: poln erotike, duhovitih indicev, gladkih razmislekov in intimnega razmišljanja in s sklepom, ki pove vse: "Ti boš zadnji. Ti boš tisti, ki mi bo vrnil devištvo. Tako neznansko sem si prizadevala, leta in leta sem se trudila odriniti prerokbo, jo potisniti nekam v prihodnost, spet pomladiti svoje telo, ga narediti lepo, da bo čutilo, da bo živelo. Toda izpolnitivi prerokbe, ko je enkrat oznanjena, se ne moremo izogniti nič bolj kot vsi tisti mogočni kralji in kraljice, vsi tisti mogočni bogovi in boginje. Kajti konec koncev, kdo pa sem jaz?"

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

An avalanche of information besets us on what to eat. It comes from the news, from influencers of every ilk, from scientists, from government, and of course from the food companies. Super foods? Ultra-processed foods? How does one find a source of trust and make intelligent choices for both us as individuals and for the society as a whole. A new book helps in this quest, a book entitled Food Intelligence: the Science of How Food Both Nourishes and Harms Us. It is written by two highly credible and thoughtful people who join us today.Julia Belluz is a journalist and a contributing opinion writer for the New York Times. She reports on medicine, nutrition, and public health. She's been a Knight Science Journalism Fellow at MIT and holds a master's in science degree from the London School of Economics and Political Science. Dr. Kevin Hall trained as a physicist as best known for pioneering work on nutrition, including research he did as senior investigator and section chief at the National Institutes of Health. His work is highly regarded. He's won awards from the NIH, from the American Society of Nutrition, the Obesity Society and the American Physiological Society. Interview Transcript Thank you both very much for being with us. And not only for being with us, but writing such an interesting book. I was really eager to read it and there's a lot in there that people don't usually come across in their normal journeys through the nutrition world. So, Julia, start off if you wouldn't mind telling us what the impetus was for you and Kevin to do this book with everything else that's out there. Yes, so there's just, I think, an absolute avalanche of information as you say about nutrition and people making claims about how to optimize diet and how best to lose or manage weight. And I think what we both felt was missing from that conversation was a real examination of how do we know what we know and kind of foundational ideas in this space. You hear a lot about how to boost or speed up your metabolism, but people don't know what metabolism is anyway. You hear a lot about how you need to maximize your protein, but what is protein doing in the body and where did that idea come from? And so, we were trying to really pair back. And I think this is where Kevin's physics training was so wonderful. We were trying to look at like what are these fundamental laws and truths. Things that we know about food and nutrition and how it works in us, and what can we tell people about them. And as we kind of went through that journey it very quickly ended up in an argument about the food environment, which I know we're going to get to. We will. It's really interesting. This idea of how do we know what we know is really fascinating because when you go out there, people kind of tell us what we know. Or at least what they think what we know. But very few people go through that journey of how did we get there. And so people can decide on their own is this a credible form of knowledge that I'm being told to pursue. So Kevin, what do you mean by food intelligence? Coming from a completely different background in physics where even as we learn about the fundamental laws of physics, it's always in this historical context about how we know what we know and what were the kind of key experiments along the way. And even with that sort of background, I had almost no idea about what happened to food once we ate it inside our bodies. I only got into this field by a happenstance series of events, which is probably too long to talk about this podcast. But to get people to have an appreciation from the basic science about what is going on inside our bodies when we eat. What is food made out of? As best as we can understand at this current time, how does our body deal with. Our food and with that sort of basic knowledge about how we know what we know. How to not be fooled by these various sound bites that we'll hear from social media influencers telling you that everything that you knew about nutrition is wrong. And they've been hiding this one secret from you that's been keeping you sick for so long to basically be able to see through those kinds of claims and have a bedrock of knowledge upon which to kind of evaluate those things. That's what we mean by food intelligence. It makes sense. Now, I'm assuming that food intelligence is sort of psychological and biological at the same time, isn't it? Because that there's what you're being told and how do you process that information and make wise choices. But there's also an intelligence the body has and how to deal with the food that it's receiving. And that can get fooled too by different things that are coming at it from different types of foods and stuff. We'll get to that in a minute, but it's a very interesting concept you have, and wouldn't it be great if we could all make intelligent choices? Julia, you mentioned the food environment. How would you describe the modern food environment and how does it shape the choices we make? It's almost embarrassing to have this question coming from you because so much of our understanding and thinking about this idea came from you. So, thank you for your work. I feel like you should be answering this question. But I think one of the big aha moments I had in the book research was talking to a neuroscientist, who said the problem in and of itself isn't like the brownies and the pizza and the chips. It's the ubiquity of them. It's that they're most of what's available, along with other less nutritious ultra-processed foods. They're the most accessible. They're the cheapest. They're kind of heavily marketed. They're in our face and the stuff that we really ought to be eating more of, we all know we ought to be eating more of, the fruits and vegetables, fresh or frozen. The legumes, whole grains. They're the least available. They're the hardest to come by. They're the least accessible. They're the most expensive. And so that I think kind of sums up what it means to live in the modern food environment. The deck is stacked against most of us. The least healthy options are the ones that we're inundated by. And to kind of navigate that, you need a lot of resources, wherewithal, a lot of thought, a lot of time. And I think that's kind of where we came out thinking about it. But if anyone is interested in knowing more, they need to read your book Food Fight, because I think that's a great encapsulation of where we still are basically. Well, Julie, it's nice of you to say that. You know what you reminded me one time I was on a panel and a speaker asks the audience, how many minutes do you live from a Dunkin Donuts? And people sort of thought about it and nobody was more than about five minutes from a Dunkin Donuts. And if I think about where I live in North Carolina, a typical place to live, I'm assuming in America. And boy, within about five minutes, 10 minutes from my house, there's so many fast-food places. And then if you add to that the gas stations that have foods and the drug store that has foods. Not to mention the supermarkets. It's just a remarkable environment out there. And boy, you have to have kind of iron willpower to not stop and want that food. And then once it hits your body, then all heck breaks loose. It's a crazy, crazy environment, isn't it? Kevin, talk to us, if you will, about when this food environment collides with human biology. And what happens to normal biological processes that tell us how much we should eat, when we should stop, what we should eat, and things like that. I think that that is one of the newer pieces that we're really just getting a handle on some of the science. It's been observed for long periods of time that if you change a rat's food environment like Tony Sclafani did many, many years ago. That rats aren't trying to maintain their weight. They're not trying to do anything other than eat whatever they feel like. And, he was having a hard time getting rats to fatten up on a high fat diet. And he gave them this so-called supermarket diet or cafeteria diet composed of mainly human foods. And they gained a ton of weight. And I think that pointed to the fact that it's not that these rats lacked willpower or something like that. That they weren't making these conscious choices in the same way that we often think humans are entirely under their conscious control about what we're doing when we make our food choices. And therefore, we criticize people as having weak willpower when they're not able to choose a healthier diet in the face of the food environment. I think the newer piece that we're sort of only beginning to understand is how is it that that food environment and the foods that we eat might be changing this internal symphony of signals that's coming from our guts, from the hormones in our blood, to our brains and the understanding that of food intake. While you might have control over an individual meal and how much you eat in that individual meal is under biological control. And what are the neural systems and how do they work inside our brains in communicating with our bodies and our environment as a whole to shift the sort of balance point where body weight is being regulated. To try to better understand this really intricate interconnection or interaction between our genes, which are very different between people. And thousands of different genes contributing to determining heritability of body size in a given environment and how those genes are making us more or less susceptible to these differences in the food environment. And what's the underlying biology? I'd be lying to say if that we have that worked out. I think we're really beginning to understand that, but I hope what the book can give people is an appreciation for the complexity of those internal signals and that they exist. And that food intake isn't entirely under our control. And that we're beginning to unpack the science of how those interactions work. It's incredibly interesting. I agree with you on that. I have a slide that I bet I've shown a thousand times in talks that I think Tony Sclafani gave me decades ago that shows laboratory rats standing in front of a pile of these supermarket foods. And people would say, well, of course you're going to get overweight if that's all you eat. But animals would eat a healthy diet if access to it. But what they did was they had the pellets of the healthy rat chow sitting right in that pile. Exactly. And the animals ignore that and overeat the unhealthy food. And then you have this metabolic havoc occur. So, it seems like the biology we've all inherited works pretty well if you have foods that we've inherited from the natural environment. But when things become pretty unnatural and we have all these concoctions and chemicals that comprise the modern food environment the system really breaks down, doesn't it? Yeah. And I think that a lot of people are often swayed by the idea as well. Those foods just taste better and that might be part of it. But I think that what we've come to realize, even in our human experiments where we change people's food environments... not to the same extent that Tony Sclafani did with his rats, but for a month at a time where we ask people to not be trying to gain or lose weight. And we match certain food environments for various nutrients of concern. You know, they overeat diets that are higher in these so-called ultra-processed foods and they'd spontaneously lose weight when we remove those from the diet. And they're not saying that the foods are any more or less pleasant to eat. There's this underlying sort of the liking of foods is somewhat separate from the wanting of foods as neuroscientists are beginning to understand the different neural pathways that are involved in motivation and reward as opposed to the sort of just the hedonic liking of foods. Even the simple explanation of 'oh yeah, the rats just like the food more' that doesn't seem to be fully explaining why we have these behaviors. Why it's more complicated than a lot of people make out. Let's talk about ultra-processed foods and boy, I've got two wonderful people to talk to about that topic. Julia, let's start with your opinion on this. So tell us about ultra-processed foods and how much of the modern diet do they occupy? So ultra-processed foods. Obviously there's an academic definition and there's a lot of debate about defining this category of foods, including in the US by the Health and Human Services. But the way I think about it is like, these are foods that contain ingredients that you don't use in your home kitchen. They're typically cooked. Concocted in factories. And they now make up, I think it's like 60% of the calories that are consumed in America and in other similar high-income countries. And a lot of these foods are what researchers would also call hyper palatable. They're crossing these pairs of nutrient thresholds like carbohydrate, salt, sugar, fat. These pairs that don't typically exist in nature. So, for the reasons you were just discussing they seem to be particularly alluring to people. They're again just like absolutely ubiquitous and in these more developed contexts, like in the US and in the UK in particular. They've displaced a lot of what we would think of as more traditional food ways or ways that people were eating. So that's sort of how I think about them. You know, if you go to a supermarket these days, it's pretty hard to find a part of the supermarket that doesn't have these foods. You know, whole entire aisles of processed cereals and candies and chips and soft drinks and yogurts, frozen foods, yogurts. I mean, it's just, it's all over the place. And you know, given that if the average is 60% of calories, and there are plenty of people out there who aren't eating any of that stuff at all. For the other people who are, the number is way higher. And that, of course, is of great concern. So there have been hundreds of studies now on ultra-processed foods. It was a concept born not that long ago. And there's been an explosion of science and that's all for the good, I think, on these ultra-processed foods. And perhaps of all those studies, the one discussed most is one that you did, Kevin. And because it was exquisitely controlled and it also produced pretty striking findings. Would you describe that original study you did and what you found? Sure. So, the basic idea was one of the challenges that we have in nutrition science is accurately measuring how many calories people eat. And the best way to do that is to basically bring people into a laboratory and measure. Give them a test meal and measure how many calories they eat. Most studies of that sort last for maybe a day or two. But I always suspected that people could game the system if for a day or two, it's probably not that hard to behave the way that the researcher wants, or the subject wants to deceive the researcher. We decided that what we wanted to do was bring people into the NIH Clinical Center. Live with us for a month. And in two two-week blocks, we decided that we would present them with two different food environments essentially that both provided double the number of calories that they would require to maintain their body weight. Give them very simple instructions. Eat as much or as little as you'd like. Don't be trying to change your weight. We're not going to tell you necessarily what the study's about. We're going to measure lots of different things. And they're blinded to their weight measurements and they're wearing loose fitting scrubs and things like that, so they can't tell if their clothes are getting tighter or looser. And so, what we did is in for one two-week block, we presented people with the same number of calories, the same amount of sugar and fat and carbs and fiber. And we gave them a diet that was composed of 80% of calories coming from these ultra-processed foods. And the other case, we gave them a diet that was composed of 0% of calories from ultra-processed food and 80% of the so-called minimally processed food group. And what we then did was just measured people's leftovers essentially. And I say we, it was really the chefs and the dieticians at the clinical center who are doing all the legwork on this. But what we found was pretty striking, which was that when people were exposed to this highly ultra-processed food environment, despite being matched for these various nutrients of concern, they overate calories. Eating about 500 calories per day on average, more than the same people in the minimally processed diet condition. And they gained weight and gained body fat. And, when they were in the minimally processed diet condition, they spontaneously lost weight and lost body fat without trying in either case, right? They're just eating to the same level of hunger and fullness and overall appetite. And not reporting liking the meals any more or less in one diet versus the other. Something kind of more fundamental seemed to have been going on that we didn't fully understand at the time. What was it about these ultra-processed foods? And we were clearly getting rid of many of the things that promote their intake in the real world, which is that they're convenient, they're cheap, they're easy to obtain, they're heavily marketed. None of that was at work here. It was something really about the meals themselves that we were providing to people. And our subsequent research has been trying to figure out, okay, well what were the properties of those meals that we were giving to these folks that were composed primarily of ultra-processed foods that were driving people to consume excess calories? You know, I've presented your study a lot when I give talks. It's nice hearing it coming from you rather than me. But a couple of things that interest me here. You use people as their own controls. Each person had two weeks of one diet and two weeks of another. That's a pretty powerful way of providing experimental control. Could you say just a little bit more about that? Yeah, sure. So, when you design a study, you're trying to maximize the efficiency of the study to get the answers that you want with the least number of participants while still having good control and being able to design the study that's robust enough to detect a meaningful effect if it exists. One of the things that you do when you analyze studies like that or design studies like that, you could just randomize people to two different groups. But given how noisy and how different between people the measurement of food intake is we would've required hundreds of people in each group to detect an effect like the one that we discovered using the same person acting as their own control. We would still be doing the study 10 years later as opposed to what we were able to do in this particular case, which is completed in a year or so for that first study. And so, yeah, when you kind of design a study that way it's not always the case that you get that kind of improvement in statistical power. But for a measurement like food intake, it really is necessary to kind of do these sorts of crossover type studies where each person acts as their own control. So put the 500 calorie increment in context. Using the old fashioned numbers, 3,500 calories equals a pound. That'd be about a pound a week or a lot of pounds over a year. But of course, you don't know what would happen if people were followed chronically and all that. But still 500 calories is a whopping increase, it seems to me. It sure is. And there's no way that we would expect it to stay at that constant level for many, many weeks on end. And I think that's one of the key questions going forward is how persistent is that change. And how does something that we've known about and we discuss in our books the basic physiology of how both energy expenditure changes as people gain and lose weight, as well as how does appetite change in a given environment when they gain and lose weight? And how do those two processes eventually equate at a new sort of stable body weight in this case. Either higher or lower than when people started the program of this diet manipulation. And so, it's really hard to make those kinds of extrapolations. And that's of course, the need for further research where you have longer periods of time and you, probably have an even better control over their food environment as a result. I was surprised when I first read your study that you were able to detect a difference in percent body fat in such a short study. Did that surprise you as well? Certainly the study was not powered to detect body fat changes. In other words, we didn't know even if there were real body fat changes whether or not we would have the statistical capabilities to do that. We did use a method, DXA, which is probably one of the most precise and therefore, if we had a chance to measure it, we had the ability to detect it as opposed to other methods. There are other methods that are even more precise, but much more expensive. So, we thought that we had a chance to detect differences there. Other things that we use that we also didn't think that we necessarily would have a chance to detect were things like liver fat or something like that. Those have a much less of an ability. It's something that we're exploring now with our current study. But, again, it's all exploratory at that point. So what can you tell us about your current study? We just wrapped it up, thankfully. What we were doing was basically re-engineering two new ultra-processed diets along parameters that we think are most likely the mechanisms by which ultra-processed meals drove increased energy intake in that study. One was the non-beverage energy density. In other words, how many calories per gram of food on the plate, not counting the beverages. Something that we noticed in the first study was that ultra-processed foods, because they're essentially dried out in the processing for reasons of food safety to prevent bacterial growth and increased shelf life, they end up concentrating the foods. They're disrupting the natural food matrix. They last a lot longer, but as a result, they're a more concentrated form of calories. Despite being, by design, we chose the overall macronutrients to be the same. They weren't necessarily higher fat as we often think of as higher energy density. What we did was we designed an ultra-processed diet that was low in energy density to kind of match the minimally processed diet. And then we also varied the number of individual foods that were deemed hyper palatable according to kind of what Julia said that crossed these pairs of thresholds for fat and sugar or fat and salt or carbs and salt. What we noticed in the first study was that we presented people with more individual foods on the plate that had these hyper palatable combinations. And I wrestle with the term terminology a little bit because I don't necessarily think that they're working through the normal palatability that they necessarily like these foods anymore because again, we asked people to rate the meals and they didn't report differences. But something about those combinations, regardless of what you call them, seemed to be driving that in our exploratory analysis of the first study. We designed a diet that was high in energy density, but low in hyper palatable foods, similar to the minimally processed. And then their fourth diet is with basically low in energy density and hyper palatable foods. And so, we presented some preliminary results last year and what we were able to show is that when we reduced both energy density and the number of hyper palatable foods, but still had 80% of calories from ultra-processed foods, that people more or less ate the same number of calories now as they did when they were the same people were exposed to the minimally processed diet. In fact they lost weight, to a similar extent as the minimally processed diet. And that suggests to me that we can really understand mechanisms at least when it comes to calorie intake in these foods. And that might give regulators, policy makers, the sort of information that they need in order to target which ultra-processed foods and what context are they really problematic. It might give manufacturers if they have the desire to kind of reformulate these foods to understand which ones are more or less likely to cause over consumption. So, who knows? We'll see how people respond to that and we'll see what the final results are with the entire study group that, like I said, just finished, weeks ago. I respond very positively to the idea of the study. The fact that if people assume ultra-processed foods are bad actors, then trying to find out what it is about them that's making the bad actors becomes really important. And you're exactly right, there's a lot of pressure on the food companies now. Some coming from public opinion, some coming from parts of the political world. Some from the scientific world. And my guess is that litigation is going to become a real actor here too. And the question is, what do you want the food industry to do differently? And your study can really help inform that question. So incredibly valuable research. I can't wait to see the final study, and I'm really delighted that you did that. Let's turn our attention for a minute to food marketing. Julia, where does food marketing fit in all this? Julia - What I was very surprised to find while we were researching the book was this deep, long history of calls against marketing junk food in particular to kids. I think from like the 1950s, you have pediatrician groups and other public health professionals saying, stop this. And anyone who has spent any time around small children knows that it works. We covered just like a little, it was from an advocacy group in the UK that exposed aid adolescents to something called Triple Dip Chicken. And then asked them later, pick off of this menu, I think it was like 50 items, which food you want to order. And they all chose Triple Dip chicken, which is, as the name suggests, wasn't the healthiest thing to choose on the menu. I think we know obviously that it works. Companies invest a huge amount of money in marketing. It works even in ways like these subliminal ways that you can't fully appreciate to guide our food choices. Kevin raised something really interesting was that in his studies it was the foods. So, it's a tricky one because it's the food environment, but it's also the properties of the foods themselves beyond just the marketing. Kevin, how do you think about that piece? I'm curious like. Kevin - I think that even if our first study and our second study had turned out there's no real difference between these artificial environments that we've put together where highly ultra-processed diets lead to excess calorie intake. If that doesn't happen, if it was just the same, it wouldn't rule out the fact that because these foods are so heavily marketed, because they're so ubiquitous. They're cheap and convenient. And you know, they're engineered for many people to incorporate into their day-to-day life that could still promote over consumption of calories. We just remove those aspects in our very artificial food environment. But of course, the real food environment, we're bombarded by these advertisements and the ubiquity of the food in every place that you sort of turn. And how they've displaced healthy alternatives, which is another mechanism by which they could cause harm, right? It doesn't even have to be the foods themselves that are harmful. What do they displace? Right? We only have a certain amount the marketers called stomach share, right? And so, your harm might not be necessarily the foods that you're eating, but the foods that they displaced. So even if our experimental studies about the ultra-processed meals themselves didn't show excess calorie intake, which they clearly did, there's still all these other mechanisms to explore about how they might play a part in the real world. You know, the food industry will say that they're agnostic about what foods they sell. They just respond to demand. That seems utter nonsense to me because people don't overconsume healthy foods, but they do overconsume the unhealthy ones. And you've shown that to be the case. So, it seems to me that idea that they can just switch from this portfolio of highly processed foods to more healthy foods just doesn't work out for them financially. Do you think that's right? I honestly don't have that same sort of knee jerk reaction. Or at least I perceive it as a knee jerk reaction, kind of attributing malice in some sense to the food industry. I think that they'd be equally happy if they could get you to buy a lot and have the same sort of profit margins, a lot of a group of foods that was just as just as cheap to produce and they could market. I think that you could kind of turn the levers in a way that that would be beneficial. I mean, setting aside for example, that diet soda beverages are probably from every randomized control trial that we've seen, they don't lead to the same amount of weight gain as the sugar sweetened alternatives. They're just as profitable to the beverage manufacturers. They sell just as many of them. Now they might have other deleterious consequences, but I don't think that it's necessarily the case that food manufacturers have to have these deleterious or unhealthy foods as their sole means of attaining profit. Thanks for that. So, Julia, back to you. You and Kevin point out in your book some of the biggest myths about nutrition. What would you say some of them are? I think one big, fundamental, overarching myth is this idea that the problem is in us. That this rise of diet related diseases, this explosion that we've seen is either because of a lack of willpower. Which you have some very elegant research on this that we cite in the book showing willpower did not collapse in the last 30, 40 years of this epidemic of diet related disease. But it's even broader than that. It's a slow metabolism. It's our genes. Like we put the problem on ourselves, and we don't look at the way that the environment has changed enough. And I think as individuals we don't do that. And so much of the messaging is about what you Kevin, or you Kelly, or you Julia, could be doing better. you know, do resistance training. Like that's the big thing, like if you open any social media feed, it's like, do more resistance training, eat more protein, cut out the ultra-processed foods. What about the food environment? What about the leaders that should be held accountable for helping to perpetuate these toxic food environments? I think that that's this kind of overarching, this pegging it and also the rise of personalized nutrition. This like pegging it to individual biology instead of for whatever the claim is, instead of thinking about how did environments and don't want to have as part of our lives. So that's kind of a big overarching thing that I think about. It makes sense. So, let's end on a positive note. There's a lot of reason to be concerned about the modern food environment. Do you see a helpful way forward and what might be done about this? Julia, let's stay with you. What do you think? I think so. We spent a lot of time researching history for this book. And a lot of things that seem impossible are suddenly possible when you have enough public demand and enough political will and pressure. There are so many instances and even in the history of food. We spend time with this character Harvey Wiley, who around the turn of the century, his research was one of the reasons we have something like the FDA protecting the food supply. That gives me a lot of hope. And we are in this moment where a lot of awareness is being raised about the toxic food environment and all these negative attributes of food that people are surrounded by. I think with enough organization and enough pressure, we can see change. And we can see this kind of flip in the food environment that I think we all want to see where healthier foods become more accessible, available, affordable, and the rest of it. Sounds good. Kevin, what are your thoughts? Yes, I just extend that to saying that for the first time in history, we sort of know what the population of the planet is going to be that we have to feed in the future. We're not under this sort of Malthusian threat of not being able to know where the population growth is going to go. We know it's going to be roughly 10 billion people within the next century. And we know we've got to change the way that we produce and grow food for the planet as well as for the health of people. We know we've got to make changes anyway. And we're starting from a position where per capita, we're producing more protein and calories than any other time in human history, and we're wasting more food. We actually know we're in a position of strength. We don't have to worry so acutely that we won't be able to provide enough food for everybody. It's what kind of food are we going to produce? How are we going to produce it in the way that's sustainable for both people and the planet? We have to tackle that anyway. And for the folks who had experienced the obesity epidemic or finally have drugs to help them and other kinds of interventions to help them. That absolve them from this idea that it's just a matter of weak willpower if we finally have some pharmaceutical interventions that are useful. So, I do see a path forward. Whether or not we take that is another question. Bios Dr. Kevin Hall is the section chief of Integrative Physiology Section in the Laboratory of Biological Modeling at the NIH National Institute of Diabetes and Digestive and Kidney Diseases. Kevin's laboratory investigates the integrative physiology of macronutrient metabolism, body composition, energy expenditure, and control of food intake. His main goal is to better understand how the food environment affects what we eat and how what we eat affects our physiology. He performs clinical research studies as well as developing mathematical models and computer simulations to better understand physiology, integrate data, and make predictions. In recent years, he has conducted randomized clinical trials to study how diets high in ultra-processed food may cause obesity and other chronic diseases. He holds a Ph.D. from McGill University. Julia Belluz is a Paris-based journalist and a contributing opinion writer to the New York Times, she has reported extensively on medicine, nutrition, and global public health from Canada, the US, and Europe. Previously, Julia was Vox's senior health correspondent in Washington, DC, a Knight Science Journalism fellow at the Massachusetts Institute of Technology in Cambridge, and she worked as a reporter in Toronto and London. Her writing has appeared in a range of international publications, including the BMJ, the Chicago Tribune, the Economist, the Globe and Mail, Maclean's, the New York Times, ProPublica, and the Times of London. Her work has also had an impact, helping improve policies on maternal health and mental healthcare for first responders at the hospital- and state-level, as well as inspiring everything from scientific studies to an opera. Julia has been honored with numerous journalism awards, including the 2016 Balles Prize in Critical Thinking, the 2017 American Society of Nutrition Journalism Award, and three Canadian National Magazine Awards (in 2007 and 2013). In 2019, she was a National Academies of Sciences, Engineering, and Medicine Communications Award finalist. She contributed chapters on public health journalism in the Tactical Guide to Science Journalism, To Save Humanity: What Matters Most for a Healthy Future, and was a commissioner for the Global Commission on Evidence to Address Societal Challenges.

Remember “The Biggest Loser”—the show where people tried to lose as much weight as quickly as possible for a big cash prize? The premise of the show was that weight loss was about willpower: With enough discipline, anyone can have the body they want.The show's approach was problematic, but how does its attitude toward weight loss match our current understanding of health and metabolism? The authors of the book Food Intelligence, nutrition scientist Kevin Hall, who studied “Biggest Loser” contestants at the NIH; and science writer Julia Belluz, join Host Flora Lichtman and answer listener questions about nutrition, diet fads, and metabolism.Read an excerpt of Food Intelligence: The Science of How Food Both Nourishes and Harms Us.Guests:Julia Belluz is a science journalist based in Paris.Dr. Kevin Hall is a nutrition scientist and former NIH researcher based in Kensington, Maryland.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

From internet service providers facing billion-dollar lawsuits for their users' file sharing to Amazon's smart displays turning into ad machines, the future of your connected life is up for grabs. If you want to know who's really pulling the strings in tech and where the battle lines are being drawn, this is the episode you can't miss. October Term 2025 Supreme Court denies Google's request to pause Play Store changes while it appeals Epic case I Want A New Drug. A Vaccine Even. And A Functioning FDA, CDC, NIH, Etc... AI videos of dead celebrities are horrifying many of their families Amazon's giant ads have ruined the Echo Show Chat Control: Germany says NEIN Apple Banned an App That Simply Archived Videos of ICE Abuses China Flexed. Trump Hit Back. So Much for the Thaw. Taiwan sees no significant impact on chip sector from China rare earths curbs FCC Chair Brendan Carr says major US online retailers have removed several million listings for prohibited Chinese electronics as part of the agency's crackdown Windows 10 support ends October 14, but here's how to get an extra year for free California bans loud commercials on Netflix, Hulu, and other streaming services Synology Reverses Policy Banning Third-Party HDDs After NAS sales plummet TiVo Exiting Legacy DVR Business - Media Play News Introducing Figure 03 Host: Leo Laporte Guests: Cathy Gellis, Jennifer Pattison Tuohy, and Gary Rivlin Download or subscribe to This Week in Tech at https://twit.tv/shows/this-week-in-tech Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: fieldofgreens.com Promo Code "TWIT" NetSuite.com/TWIT shopify.com/twit bitwarden.com/twit expressvpn.com/twit

From internet service providers facing billion-dollar lawsuits for their users' file sharing to Amazon's smart displays turning into ad machines, the future of your connected life is up for grabs. If you want to know who's really pulling the strings in tech and where the battle lines are being drawn, this is the episode you can't miss. October Term 2025 Supreme Court denies Google's request to pause Play Store changes while it appeals Epic case I Want A New Drug. A Vaccine Even. And A Functioning FDA, CDC, NIH, Etc... AI videos of dead celebrities are horrifying many of their families Amazon's giant ads have ruined the Echo Show Chat Control: Germany says NEIN Apple Banned an App That Simply Archived Videos of ICE Abuses China Flexed. Trump Hit Back. So Much for the Thaw. Taiwan sees no significant impact on chip sector from China rare earths curbs FCC Chair Brendan Carr says major US online retailers have removed several million listings for prohibited Chinese electronics as part of the agency's crackdown Windows 10 support ends October 14, but here's how to get an extra year for free California bans loud commercials on Netflix, Hulu, and other streaming services Synology Reverses Policy Banning Third-Party HDDs After NAS sales plummet TiVo Exiting Legacy DVR Business - Media Play News Introducing Figure 03 Host: Leo Laporte Guests: Cathy Gellis, Jennifer Pattison Tuohy, and Gary Rivlin Download or subscribe to This Week in Tech at https://twit.tv/shows/this-week-in-tech Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: fieldofgreens.com Promo Code "TWIT" NetSuite.com/TWIT shopify.com/twit bitwarden.com/twit expressvpn.com/twit

From internet service providers facing billion-dollar lawsuits for their users' file sharing to Amazon's smart displays turning into ad machines, the future of your connected life is up for grabs. If you want to know who's really pulling the strings in tech and where the battle lines are being drawn, this is the episode you can't miss. October Term 2025 Supreme Court denies Google's request to pause Play Store changes while it appeals Epic case I Want A New Drug. A Vaccine Even. And A Functioning FDA, CDC, NIH, Etc... AI videos of dead celebrities are horrifying many of their families Amazon's giant ads have ruined the Echo Show Chat Control: Germany says NEIN Apple Banned an App That Simply Archived Videos of ICE Abuses China Flexed. Trump Hit Back. So Much for the Thaw. Taiwan sees no significant impact on chip sector from China rare earths curbs FCC Chair Brendan Carr says major US online retailers have removed several million listings for prohibited Chinese electronics as part of the agency's crackdown Windows 10 support ends October 14, but here's how to get an extra year for free California bans loud commercials on Netflix, Hulu, and other streaming services Synology Reverses Policy Banning Third-Party HDDs After NAS sales plummet TiVo Exiting Legacy DVR Business - Media Play News Introducing Figure 03 Host: Leo Laporte Guests: Cathy Gellis, Jennifer Pattison Tuohy, and Gary Rivlin Download or subscribe to This Week in Tech at https://twit.tv/shows/this-week-in-tech Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: fieldofgreens.com Promo Code "TWIT" NetSuite.com/TWIT shopify.com/twit bitwarden.com/twit expressvpn.com/twit

From internet service providers facing billion-dollar lawsuits for their users' file sharing to Amazon's smart displays turning into ad machines, the future of your connected life is up for grabs. If you want to know who's really pulling the strings in tech and where the battle lines are being drawn, this is the episode you can't miss. October Term 2025 Supreme Court denies Google's request to pause Play Store changes while it appeals Epic case I Want A New Drug. A Vaccine Even. And A Functioning FDA, CDC, NIH, Etc... AI videos of dead celebrities are horrifying many of their families Amazon's giant ads have ruined the Echo Show Chat Control: Germany says NEIN Apple Banned an App That Simply Archived Videos of ICE Abuses China Flexed. Trump Hit Back. So Much for the Thaw. Taiwan sees no significant impact on chip sector from China rare earths curbs FCC Chair Brendan Carr says major US online retailers have removed several million listings for prohibited Chinese electronics as part of the agency's crackdown Windows 10 support ends October 14, but here's how to get an extra year for free California bans loud commercials on Netflix, Hulu, and other streaming services Synology Reverses Policy Banning Third-Party HDDs After NAS sales plummet TiVo Exiting Legacy DVR Business - Media Play News Introducing Figure 03 Host: Leo Laporte Guests: Cathy Gellis, Jennifer Pattison Tuohy, and Gary Rivlin Download or subscribe to This Week in Tech at https://twit.tv/shows/this-week-in-tech Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: fieldofgreens.com Promo Code "TWIT" NetSuite.com/TWIT shopify.com/twit bitwarden.com/twit expressvpn.com/twit

According to a 2024 World Health Organization study, over the last 50 years vaccines have saved over 154 million lives worldwide from over 20 life threatening diseases. As vaccines are facing skepticism, we are here to cut through the noise and lay out the facts as to why staying up-to-date on vaccinations is especially important for kidney patients. This episode is supported by Moderna.  In today's episode we heard from:  Mary Baliker has been a dedicated healthcare advocate for the past 40 years, and is involved in several kidney initiatives regionally, nationally and globally. Mary was diagnosed with a rare kidney disease at the age of nine and since then has undergone hemodialysis and received four kidney transplants. As a result of this life-long journey, Mary cherishes her life and possesses a strong desire to help improve the healthcare experience, health outcomes and quality of life for patients with kidney disease. In addition to publishing multiple peer reviewed articles related to the kidney patient experience, Mary is the author of Maria Never Gives Up, a story written to help children and families facing chronic illnesses. Her book is distributed across transplant and dialysis centers nationwide and is available for purchase online William Werbel, MD, PhD is a transplant infectious diseases physician and scientist at Johns Hopkins focused on optimizing protection against infections in immunocompromised persons. He completed clinical and research fellowship in infectious diseases at Johns Hopkins following MD training at the University of Michigan and internal medicine residency and chief residency at the Northwestern Feinberg School of Medicine. He is the current Associate Director for Epidemiology and Quantitative Sciences in the Johns Hopkins Transplant Research Center and principal investigator of the national Emerging Pathogens of Concern in Immunocompromised Persons (EPOC) cohort study. He receives NIH funding to study the landscape of infections in transplant recipients and evaluate the real-world impact of vaccination using a combination of epidemiological and laboratory approaches. Additional Resources: Vaccines for CKD Patients Vaccine Integrity Project IDSA Immunization Resources Emerging Pathogens of Concern in Immunocompromised Persons (EPOC) Study   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

Jon Hartley and Jay Bhattacharya discuss Jay Bhattacharya's vision for the National Institutes of Health (NIH), running the NIH as an innovation accelerator, replication in the sciences, measuring scientist productivity, and the new NIH policy reducing animal testing. Recorded on August 27, 2025. ABOUT THE SERIES Each episode of Capitalism and Freedom in the 21st Century, a video podcast series and the official podcast of the Hoover Economic Policy Working Group, focuses on getting into the weeds of economics, finance, and public policy on important current topics through one-on-one interviews. Host Jon Hartley asks guests about their main ideas and contributions to academic research and policy. The podcast is titled after Milton Friedman‘s famous 1962 bestselling book Capitalism and Freedom, which after 60 years, remains prescient from its focus on various topics which are now at the forefront of economic debates, such as monetary policy and inflation, fiscal policy, occupational licensing, education vouchers, income share agreements, the distribution of income, and negative income taxes, among many other topics. For more information about the podcast, or subscribe for the next episode, click here.

From internet service providers facing billion-dollar lawsuits for their users' file sharing to Amazon's smart displays turning into ad machines, the future of your connected life is up for grabs. If you want to know who's really pulling the strings in tech and where the battle lines are being drawn, this is the episode you can't miss. October Term 2025 Supreme Court denies Google's request to pause Play Store changes while it appeals Epic case I Want A New Drug. A Vaccine Even. And A Functioning FDA, CDC, NIH, Etc... AI videos of dead celebrities are horrifying many of their families Amazon's giant ads have ruined the Echo Show Chat Control: Germany says NEIN Apple Banned an App That Simply Archived Videos of ICE Abuses China Flexed. Trump Hit Back. So Much for the Thaw. Taiwan sees no significant impact on chip sector from China rare earths curbs FCC Chair Brendan Carr says major US online retailers have removed several million listings for prohibited Chinese electronics as part of the agency's crackdown Windows 10 support ends October 14, but here's how to get an extra year for free California bans loud commercials on Netflix, Hulu, and other streaming services Synology Reverses Policy Banning Third-Party HDDs After NAS sales plummet TiVo Exiting Legacy DVR Business - Media Play News Introducing Figure 03 Host: Leo Laporte Guests: Cathy Gellis, Jennifer Pattison Tuohy, and Gary Rivlin Download or subscribe to This Week in Tech at https://twit.tv/shows/this-week-in-tech Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: fieldofgreens.com Promo Code "TWIT" NetSuite.com/TWIT shopify.com/twit bitwarden.com/twit expressvpn.com/twit

If you're enjoying the content, please like, subscribe, and comment! Dr. Schwartz's Links: Website: https://www.theodorehschwartzmd.com/ Book: https://www.penguinrandomhouse.com/books/734286/gray-matters-by-theodore-h-schwartz/ Theodore H. Schwartz, MD graduated Magna Cum Laude in Philosophy and English from Harvard University and Magna Cum Laude in Neuroscience from Harvard Medical School. After completing his residency and chief residency in Neurosurgery at The Neurological Institute of New York at Columbia-Presbyterian Medical Center, Dr. Schwartz spent a year at Yale-New Haven Medical Center where he received advanced fellowship training in epilepsy and brain tumor surgery. He completed a post-doctoral fellowship at the Max Planck Institute in Munich, Germany funded by the Van Wagenen Fellowship and the Von Humboldt Society. Dr. Schwartz spent 25 years as a Professor of Neurosurgery, Otolaryngology, and Neuroscience at Weill Cornell Medical College, New York Presbyterian Hospital. He was named David and Ursel Barnes Professor in Minimally Invasive Surgery, the first endowed professorship in the department, Vice-Chairman of Clinical Research, the Director of Anterior Skull Base and Pituitary Surgery, Co-Director of Surgical Neuro-Oncology, the Director of Epilepsy Surgery, and ran a basic science laboratory investigating the causes and treatment for epilepsy. He has received K08, R01 and R21 funding from the NINDS for his research and has served on several NIH review committees.Dr. Schwartz's book Gray Matters: A Biography of Brain Surgery, published by Dutton/Penguin-Random House, was selected by The Economist as one of the best books of 2024. His nonfiction writing has been featured in the Wall Steet Journal, the Boston Globe, Psyche Magazine, and The Psychologist. Dr. Schwartz is currently the Founder and CEO of a med tech device company called illumination Diagnostics._______________________Follow us!@worldxppodcast Instagram - https://bit.ly/3eoBwyr@worldxppodcast Twitter - https://bit.ly/2Oa7BzmSpotify - http://spoti.fi/3sZAUTGYouTube - http://bit.ly/3rxDvUL#neuroscience #surgeon #medschool #medical #neurosurgeon #surgery #medicine #medicalstudent #cte #tbi #trauma #traumaticbraininjury #concussion #subscribe #explore #explorepage #podcastshow #longformpodcast #podcasts #podcaster #podcasting #worldxppodcast #viralvideo #youtubeshorts

From internet service providers facing billion-dollar lawsuits for their users' file sharing to Amazon's smart displays turning into ad machines, the future of your connected life is up for grabs. If you want to know who's really pulling the strings in tech and where the battle lines are being drawn, this is the episode you can't miss. October Term 2025 Supreme Court denies Google's request to pause Play Store changes while it appeals Epic case I Want A New Drug. A Vaccine Even. And A Functioning FDA, CDC, NIH, Etc... AI videos of dead celebrities are horrifying many of their families Amazon's giant ads have ruined the Echo Show Chat Control: Germany says NEIN Apple Banned an App That Simply Archived Videos of ICE Abuses China Flexed. Trump Hit Back. So Much for the Thaw. Taiwan sees no significant impact on chip sector from China rare earths curbs FCC Chair Brendan Carr says major US online retailers have removed several million listings for prohibited Chinese electronics as part of the agency's crackdown Windows 10 support ends October 14, but here's how to get an extra year for free California bans loud commercials on Netflix, Hulu, and other streaming services Synology Reverses Policy Banning Third-Party HDDs After NAS sales plummet TiVo Exiting Legacy DVR Business - Media Play News Introducing Figure 03 Host: Leo Laporte Guests: Cathy Gellis, Jennifer Pattison Tuohy, and Gary Rivlin Download or subscribe to This Week in Tech at https://twit.tv/shows/this-week-in-tech Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: fieldofgreens.com Promo Code "TWIT" NetSuite.com/TWIT shopify.com/twit bitwarden.com/twit expressvpn.com/twit

What if everything you thought you knew about cholesterol was wrong? Today on ‘The Dr. Bob MartinShow', we're diving into a groundbreaking NIH discovery that's rewriting the rules of heart health. For the first time, scientists have captured LDL cholesterol in action—revealing how it binds to its receptor and what happens when that process goes wrong. From the surprising truth about statins to the future of personalized cholesterol treatments, this episode will change how you think about your heart health. Plus, we'll break down what your cholesterol numbers really mean and how you can take control of your health.Special Guest: Jim LaValle - clinical pharmacist, author, and board-certified clinicalnutritionist

In this episode, Meghan Gutierrez, CEO of the Lymphoma Research Foundation, shares insights on how proposed NIH budget cuts could impact cancer research, the importance of stable funding for early-career scientists, and how the foundation is supporting innovation and patient education to accelerate progress against lymphoma.

In our latest episode, Associate Editor Dr. Jason Carter (Baylor University, Robbins College of Health and Human Sciences) interviews authors Dr. Alex Carll and Brittany Reynolds (University of Louisville School of Medicine), along with expert Dr. Jessica Bradshaw (University of North Texas Health Science Center), about the recent work by Reynolds et al. There are an estimated 68 million e-cigarette users worldwide, and the use of e-cigarettes during pregnancy has been on a steady rise in recent years. Evidence shows that 1 in 5 smokers or ex-smokers who become pregnant use e-cigarettes during pregnancy, yet the effects of vaping on maternal health during and after pregnancy are poorly understood. Reynolds et al. developed a preclinical mouse model of e-cigarette use during pregnancy to assess maternal autonomic control and ventricular arrhythmias, which further solidifies the relevance of animal research to the NIH mission to enhance health, lengthen life, and reduce illness and disability. The authors measured the dams at 3 weeks postpartum and found lasting increases in catecholamines, which indicates increased sympathetic activation. In addition, the authors found increases in the occurrence of spontaneous ventricular premature beats, which are indications of increased risk for sudden cardiac death and heart failure. What impact does vaping have on maternal cardiovascular health, both during pregnancy and in the postpartum period? Listen now to find out more.   Brittany R. Reynolds, Sean M. Raph, Anand Ramalingam, Shweta Srivastava, Pawel Lorkiewicz, Lillian E. Watson, Kenneth R. Brittian, Helen E. Collins, and Alex P. Carll Don't go vaping my heart: e-cigarette exposure during pregnancy promotes peripartum ventricular arrhythmias and sympathetic dominance Am J Physiol Heart Circ Physiol, published September 22, 2025. DOI: 10.1152/ajpheart.00509.2025

  AZ Bio Week & Life Sciences Innovation w/ Joan Koerber-Walker - AZ TRT S06 EP19 (281) 10-12-2025   Things We Learned This Week AZ Bio mission to improve life and bioscience, & make AZ a Top Ten Bioscience state AZ Bio Week 2025 - Oct. - 5 Days Talks, Events & Awards AZ Advances - nonprofit donation to biotech startups Aqualung Therapeutics is treating inflammation in the lungs, get people off ventilators & save lives Calviri is working on a Vaccine to PREVENT Cancer, currently largest animal clinical trial Anuncia Medical has a Re-Flow product to help drain fluid from the brain, treats Hydrocephalus     Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   LKIN: https://www.linkedin.com/in/joankoerberwalker  www.azbio.org Bio: As President and CEO of AZBio, Joan Koerber-Walker works on behalf of the Arizona Bioscience and Medical Technology Industry to support the growth of the industry, its members and our community on the local and national level. Ms. Koerber-Walker is also a life science investor and has served on the boards of numerous for-profit and non-profit organizations. In the life science industry, Ms. Koerber-Walker serves as as Arizona's representative to the State Medical Technology Alliance (SMTA), a consortium of state and regional trade associations representing their local medical technology companies which she chaired in 2015 and  represents Arizona as a member of the Council of State Bioscience Associations (CSBA) and the Coalition of State Bioscience Institutes (CSBI). Active in the entrepreneurial and investment communities, she also serves as Chairman of the Board of the Opportunity Through Entrepreneurship Foundation which provides entrepreneurial education, mentoring and support to at-risk members of the community, on the Board of Advisors to CellTrust, Inc. which provides secure communication technology to the healthcare industry, and as Chairman of CorePurpose, Inc. which she founded in 2002. Ms. Koerber-Walker has been recognized as Executive of the Year by the Arizona Society of Association Executives, as a “Most Admired Leader” by the Phoenix Business Journal (2015),  in the pages of AZ Business Leaders (2013 thru 2020), Most Influential Women in Arizona Business (2014) and is a 2 time National Finalist for the Stevie Award which recognizes the work of women in business. Her past experience includes two years as the CEO of ASBA (the Arizona Small Business Association), service as a member of the Board of Trustees of the National Small Business Association in Washington D.C., President of the National Speakers Association/Arizona, Chair of the Board of Advisors to Parenting Arizona, the state's largest child abuse prevention organization, & much more.         AZBio:  Supporting Arizona's Life Science Industry for 19 Years (2003 – 2022) Learn more about Arizona's bioindustry: www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO We're part of a movement to create sustainable funding for life science innovation in Arizona. Learn more at www.AZAdvances.org  MOVING LIFE SCIENCE INNOVATIONS ALONG THE PATH FROM DISCOVERY TO DEVELOPMENT TO DELIVERY OUR VISION OF THE FUTURE: Arizona is a top-ten life science state. OUR MISSION: AZBio supports the needs of Arizona's growing life science ecosystem. The Arizona Bioindustry Association (AZBio) is a not-for-profit, 501(c)6 trade association supporting the growth of Arizona's life science sector. AZBio  Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector.  As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.   AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.   Arizona's bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona's universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.   Notes:   Seg 1   Biotech and life sciences industry in Arizona, has 3000 businesses and 36,000 employees. The economic impact in 2021 was $38.5 billion. AZ Bio would like to double, so by 2033, the impact would be $78 billion.   Examples of biotech companies in Arizona are Medtronic that makes medical devices, WL Gore, material sciences. Other companies in diagnostics, there are Sonoran Quest which does testing. This also Castle Bio Sciences, deals in cancer treatment. Some medicine companies are Bristol, Myers, and Calvari who deals in cancer drugs. Calvari is the bio science company of the year in 2024.   AZ Bio Science Week started in 2017. AZ Bio week starts Oct. 13 (2025) and has events daily from Monday to Friday.     Example of one of the many companies involved with AZ Bio week:   CND Life Sciences - CND's Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.   NIH - National Institute of Health gives grants or funding to universities, hospitals and even companies for medical research.   Takes time to build a medical device type product, a few years to decades.   Government is an important partner, that provides financial support. Examples are Medicare research, workforce help, and tax breaks. Many organizations like this are publicly funded with government and university help.  $25 billion in funding over the last 20 years in Arizona in bio investment. Government funded $5 billion, that's from state and federal sales tax at a penny per. $112 million funding to universities in 2022. Combination of industry, government and philanthropy. Discovery phase - university helps develop the IP and research. Technology is spun out of the university to corporate development by companies. The AZ Board of Regents owns the patents. They license the patents to companies. Then you have regulatory.  Distribution of a product. Successful products are profitable. They have a royalty that pays to the company, the university and the government. Example of this was the University of Florida created Gatorade in the 1970s and still gets royalties today. Process takes 10 to 15 years, with hundreds of people involved. Clinical trials of any type of drug takes years.   Creation of the Covid vaccine was an outlier, as many people had Covid at the time so it was very easy to put together big study groups       Seg 2   Examples of newer companies in biotech field –   Neo clinical stage company dealing in heart health with aortic artery for the abdomen.   Another new company is prim dealing in MCT deficiency, compound growth and they are in clinical and testing stages.   Drugs get tested through computer models, and then on animals. Always have to worry about safety and ethics. FDA has very strict rules. You do not put people at risk, after monitor, during test and post monitoring. There's high-level quality control.       AZ Bio has members that are in the bioscience industry with current companies   AZ Advances is about bio startups in early stage companies It's a 501 C nonprofit charity that is funding, internships, and education   Patient is not only the client, but the purpose for why biotech companies exist     Neuralink Corp. is an American neurotechnology company that has developed as of 2024 implantable brain–computer interfaces. It was founded by Elon Musk and a team of eight scientists and engineers. Neuralink was launched in 2016 and first publicly reported in March 2017.   Neuralink's first human patient, Noland Arbaugh, is an Arizona native who received his implant in January 2024 at the Barrow Neurological Institute in Phoenix. He will appear at Arizona Bioscience Week 2025     https://www.azbio.org/azbw2025     Events Summary:   Monday - Women in Biotech Leading Women: Biotech & Beyond Join us for an evening of conversation and connections with our community's leading women as we kick off Arizona Bioscience Week in style!   Tuesday - Fundraising Fundraising Strategies for Life Science Startups  A compelling narrative is crucial when you are fundraising and communicating with life science investors.  This Life Science Nation (LSN) Global Fundraising Bootcamp covers topics related to executing a successful fundraise for your startup.      Wednesday – AZ Bio awards, philanthropy, entertainment, and AZ Advances The 21st Annual AZBio Awards & AZAdvances After Party Celebrate with the Educators, Researchers, and Organizations that are making life better for people in Arizona and around the world.  Join us at the Phoenix Convention Center as we honor the 2024 AZBio Award Winners. Hundreds of health innovators and business leaders will be celebrating at the 20th Annual AZBio Awards.   Thursday -  AZAdvances   AZ Advances Health Innovation Summit This exclusive event will bring together health innovation leaders to share how are moving Arizona forward as we make life better for the people we serve.   AZ Advances: Arizonans are advancing life changing and life saving innovations along the path from discovery to development to delivery. AZAdvances is developing the funding that will help advance health innovations in Arizona today and for generations to come.  Charitable donations to the AZAdvances fund at the Opportunity Through Entrepreneurship Foundation, an Arizona based 501c3 public charity, are a way to support the creation of tomorrow's medical innovations.    Friday - Voice of the Patient Patients are the reason we do what we do.  Join the conversation on life science innovation from the patient perspective.        Seg. 3 Best of AZ Bio clips:   AZ Bio & Life Sciences Innovation w/ Joan Koerber-Walker - BRT S04 EP10 (172) 3-5-2023   Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   Full Show: HERE     Guest: Stan Miele President & CBO Aqualung Therapeutics Corp LKIN: HERE www.aqualungtherapeutics.com   Stan Miele Bio: A recognized global executive with success in sales, marketing and P&L leadership in the pharmaceutical/medical device and biotech industries. Mr. Miele was formally the Chief Commercial Officer at bioLytical Laboratories and Sucampo Pharmaceuticals Inc.  He was also President of Sucampo Pharma Americas for 6 years.   He was instrumental on some key licensing agreements for Sucampo, inclusive of the agreement with Abbott Japan, and also Takeda Pharmaceuticals (now Shire).  He is actively part of the team ensuring proper execution of clinical development, manufacturing, licensing, capital funding, alliances, and ensuring Aqualung meets all critical milestones.  He will be helping the company move toward accelerating the pipeline/platform technology and moving eNamptor™ toward commercialization.   Aqualung Therapeutics  Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung's strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.   Full Show: HERE       Seg. 4 – Clips from:  Preventing Cancer with a Vaccine w/ Stephen Johnston of Calviri  - BRT S04 EP17 (179) 4-23-2023   Guest: Stephen Johnston Founding CEO, Calviri Inc.  LKIN: HERE https://calviri.com/   Bio: Chief Executive Officer & Chairman of the Board Stephen Albert Johnston is the inventor of the Calviri's central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell, Inc. He is Director of the Arizona State University Biodesign Institute's Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.     Calviri Inc.  We are determined to offer humanity a better life, free from cancer. While our goal is hugely ambitious, we are intensely driven to rid the planet of worry from cancer. Calviri's mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine.   Full Show: HERE       ReFlow to Help Treat Hydrocephalus w/ Elsa Abruzzo & Mark Geiger of Anuncia Medical - BRT S04 EP23 (186) 6-11-2023     Guest: Elsa Chi Abruzzo RAC, FRAPS – President Elsa Chi Abruzzo is a medical device executive, entrepreneur, and a founding member of Anuncia, Inc., Alcyone Therapeutics, Arthromeda, Inc. and Cygnus Regulatory. Elsa has a 30+ year successful product development, operations, regulatory, quality, and clinical track record in med tech Industries. Her experience includes leadership positions at Baxter, Cordis JNJ, CryoLife, Percutaneous Valve Technologies, AtriCure, InnerPulse, Merlin MD, Sapheon, and PTS Diagnostics. Elsa earned a BS in engineering from the University of Miami in Coral Gables, FL and is regulatory affairs certified and a Regulatory Affairs Professional Society Fellow, recognized for her leadership in Regulatory and Quality by MDDI.   https://anunciamedical.com/the-anuncia-story/#team https://www.linkedin.com/in/elsachiabruzzo/   https://anunciamedical.com/ About Anuncia Conceptualized in 2014 in collaboration with Boston Children's Hospital and spun out of Alcyone Therapeutics in 2018, Anuncia's patented portfolio of technologies are intended to provide peace-of-mind through innovation. Our core ReFlow™ technology uses a simple finger depression of a soft silicone dome located under the patient's scalp to produce a noninvasive, one-way flush of the patient's own CSF directed toward the ReFlow™ catheter to restore or increase CSF flow through a non-flowing shunt and potentially avoid emergency surgery.  Learn More     The name Anuncia comes from Panthera Uncia, the species name of the snow leopard. These animals live in mountainous regions of Asia and have been called by the World Wildlife Foundation “Guardians of the Headwaters” as they roam the headwater areas of the western basins. The origin of the word hydrocephalus comes from the Greek hudrokephalon, from hudro ‘water'+ kephalē ‘head'. The snow leopard, or Guardian of the Headwaters, is a symbol of Anuncia's dedication to improve daily quality of life for the millions of underserved patients with hydrocephalus and other CSF disorders, as well as their families, who suffer from the clinical, economic, and emotional burden of repeat revision brain surgery due to VP shunt occlusions.      Full Show: HERE           Best of Biotech from AZ Bio & Life Sciences to Jellatech: HERE   Biotech Shows: HERE   AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023      ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.

Join host Mellissa Middeldorp and her guests Mina Chung and Dominik Linz as they discuss this recent artle while in Atlanta at HRX Live 2025. In this trial the authors tested a telemedicine-based, village doctor–led integrated care model for atrial fibrillation in rural China, comparing it to usual care across 30 village clinics and over 1,000 patients. At 12 and 36 months, the intervention arm significantly improved adherence to integrated AF management and reduced composite rates of cardiovascular outcomes (death, stroke, heart failure admissions, AF emergency visits) versus control. Learning Objective Compare telemedicine based, village-doctor-led care to typical care for atrial fibrillation cases. Article Authors and Podcast Contributors  Article Authors Ming Chu, Shimeng Zhang, Jinlong Gong, Shu Yang, Gang Yang, Xingxing Sun, Dan Wu, Yaodongqin Xia, Jincheng Jiao, Xiafeng Peng, Zhihang Peng, Li Hong, Zhirong Wang, Mingfang Li, Gregory Y. H. Lip & Minglong Chen Podcast Contributors Melissa E. Middeldorp, MPH, PhD Mina K. Chung, MD, FHRS Dominik K Linz, MD, PhD   All relevant financial relationships have been mitigated. Host Disclosure(s): M. Middeldorp:   Nothing to disclose. ​Contributor Disclosure(s):    M. Chung: •Honoraria/Speaking/Consulting: University of Chicago, Cedars Sinai Medical Center, Asia Pacific Heart Rhythm Society, NIH, Baylor College of Medicine, Kansas City Heart Rhythm Symposium, American College of Cardiology, Geisinger Health Systems, ABIM, Academy for Continued Healthcare Learning, Mediasphere Medical, Western AF Symposium, University of Minnesota, Stanford University, Canadian Heart Rhythm Society •Research: NIH, American Heart Association •Royalty Income: Elsevier, Wolters Kluver •Officer: American Heart Association D. Linz Nothing to disclose.   Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.

RE-RELEASE: This episode was originally released in February 2025.In this episode, Dr. Anthony Fauci joins A'ndre for an in-depth conversation about his decades-long career in public health and his experiences leading the U.S. response to some of the world's most pressing infectious disease challenges. Dr. Fauci reflects on his early work during the HIV/AIDS crisis, the evolution of treatments that saved millions of lives, and his role in launching PEPFAR, one of the most significant global health initiatives in history. He  discusses his leadership at the National Institute of Allergy and Infectious Diseases (NIAID), navigating crises such as Ebola, Zika, H1N1, anthrax, and COVID-19, while working alongside multiple U.S. presidents to shape national and global health policies.Beyond his career in government, Dr. Fauci shares his thoughts on the intersection of public health and national security, the growing challenges of vaccine skepticism and misinformation, and the vital role of institutions like the NIH and CDC in protecting public health. He also highlights the major health threats that remain overlooked in mainstream discourse. Now a professor at Georgetown University, Dr. Fauci reflects on his transition to academia and the importance of training the next generation of medical leaders in an era of evolving global health challenges.You can purchase his recent memoir, On Call, here.

In this episode, we sit down with Dr. Olajide Williams to explore how stroke awareness, prevention, and treatment intersect with culture, equity, and the arts. He shares both personal insights and groundbreaking research that has saved lives in Harlem and beyond.Together, we discuss:* The urgent reality of stroke – why every minute counts (“time is brain”).* Why stroke disproportionately affects Black and Brown communities—and tragically, at younger ages.* The treatment window: from clot-dissolving medications like tenecteplase to advanced clot-removal procedures.* The hidden barriers to timely stroke care—knowledge gaps, delayed responses, and reliance on cabs or waiting rooms instead of calling 911.* The power of health literacy as the first pit stop on the road to health equity.* How the Hip Hop Stroke Program quadrupled treatment rates in Harlem by engaging children, who then educated their parents and grandparents.* Why music, art, and emotional connection are indispensable for learning and transforming community health.Key Insights & Gems

Because of our strong capabilities in training and technical assistance, ORAU was contracted by the National Institutes of Health to develop a state-of-the-art training center for users of the Common Fund Data Ecosystem. This ecosystem is an infrastructure to make data from the NIH's various programs easier to access with the aim of facilitating improved discovery, reuse, integration, and analyses of these datasets to form novel hypothesis for accelerating discoveries in biomedical research. In this episode of Further Together, Allissa Dillman, Ph.D., co-principal investigator and owner of BioData Sage LLC, and Jennifer Burnette, ORAU project director, talk to host Michael Holtz about the importance of the CFDE Training Center and how it can help researchers mine data for omics research of various kinds. Dillman also hosts the Decoding the Data Ecosystem Podcast, which dives deep into unraveling the complexities and exploring the depths of omics data. The podcast can be found here: https://blubrry.com/3847772/ Check out the Common Fund Data Ecosystem Training Center here: https://orau.org/cfde-trainingcenter/index.html Find the Common Fund Data Ecosystem here: https://commonfund.nih.gov/dataecosystem

FL First Lady Casey DeSantis has gone full MAHA: funding research into “overlooked” options in cancer treatment, advancing repurposed generics like ivermectin, and reshaping mental health education in schools. Now she's working with Dr. Joseph Ladapo, Surgeon General of Florida, with his biggest announcement yet: “The Florida Department of Health, in partnership with the governor, is going to be working to end all vaccine mandates in Florida law.” Florida would be the first state to end vaccination mandates for schoolchildren, and a pioneer in innovative cancer research. “Florida is looking to fill the void to advance research where the market falls short,” says Casey DeSantis. Casey DeSantis is the First Lady of Florida, championing cancer research and care, securing over $100 million in recurring funding. Declared cancer-free in February 2022, she travels the state to support patients and families. She leads initiatives like Hope Florida, Resiliency Florida, Character Education Standards, The Facts. Your Future, and Hope for Healing. Follow at https://x.com/CaseyDeSantis Dr. Joseph A. Ladapo serves as the State Surgeon General of Florida and Professor of Medicine at the University of Florida. His research explores behavioral economic strategies to reduce cardiovascular risk and includes NIH- and Robert Wood Johnson Foundation-supported trials. Follow at https://x.com/FLsurgeongen Tom Renz is an attorney, author, and political analyst, recognized for legal work during COVID-19. Learn more at http://TomRenz.com and follow him at https://x.com/RenzTom 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/sponsors⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

What happens to America’s health when Washington grinds to a halt? In this episode of The Health Advocates, we break down the latest federal government shutdown and what it means for public health agencies across the country. We explain what a shutdown actually is, drawing from past shutdowns over the last 30 years, and then dive into the immediate and long-term impacts on the CDC, FDA, NIH, and other agencies that millions of people depend on for research, vaccines, food safety, and emergency response. We also look at the political stalemate behind the shutdown, focusing on Democrats’ push to restore pending cuts to Affordable Care Act subsidies and what those cuts could mean for healthcare costs. Finally, we explore whether there’s a realistic path to resolution soon—and what’s at stake for patients and the healthcare system if Congress fails to act. Contact Our Host Steven Newmark, Chief of Policy at GHLF: snewmark@ghlf.org A podcast episode produced by Ben Blanc, Director, Digital Production and Engagement at GHLF. We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.org Listen to all episodes of The Health Advocates on our website (https://ghlf.org/the-health-advocates) or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Addiction doesn't announce itself- it emerges silently, often after a routine medical procedure. Our next guest, James Piacentino, is changing this reality as CEO and Co-Founder of Thrive Genetics. With over 20 years in healthcare technology and two successful startup exits under his belt, James brings both personal experience and professional expertise to this mission. After losing his father to opioid addiction following a routine surgery, James dedicated his career to ensuring others wouldn't face the same tragedy. By combining cutting-edge genomics with behavioral psychology, Thrive Genetics helps physicians understand a patient's addiction risk before prescribing pain medication. Join us to discover how James and his team are pioneering personalized addiction risk management, transforming how healthcare systems approach prevention, and working to spare millions of families from generational trauma. Let's go!Episode Highlights:Curiosity as the foundation for innovation: James emphasizes that deep curiosity about solving meaningful problems is the key driver that gets him out of bed every morning and the most important quality he looks for in team members.Personal tragedy sparking a mission: After losing his father to opioid addiction following a 1982 car accident and back surgery, James dedicated his career to preventing others from experiencing the same generational trauma.Staggering gap in care: Up to 25% of patients undergoing high-pain procedures become addicted to prescribed opioids, yet no proactive addiction risk assessment exists before prescribing pain medication.Science-backed solution: Thrive Genetics combines 10 years of research and over $50M in NIH grants to create addiction risk scores based on both genetic predisposition (50%) and behavioral factors (50%).Thinking beyond the individual: James' North Star is reaching billions of people by preventing not just individual addiction cases, but stopping generational family trauma before it starts.About our Guest: Thrive Genetics is led by Co-Founder and CEO, James J. Piacentino, MBA, a healthcare technology entrepreneur with over 20 years in tech and life sciences. A graduate of Northwestern University's Kellogg School of Management, James has built and sold two prior startups, published in the Harvard Business Review, and held senior leadership roles at SAP. He is mentored by Harry Kraemer, former CEO of Baxter International and Kellogg Professor of Management.Links Supporting This Episode: Thrive Genetics Website: CLICK HEREJame Piacentino LinkedIn page: CLICK HEREThrive Genetics LinkedIn: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter:

Research can seem like something that happens far off, but doesn't affect us on a daily basis. Nothing could be further from the truth! How does what we breathe cause disease? Can we intervene? If I have to choose, should I buy an air purifier or an air conditioner? How much does that help? What about if I have a family member with lung disease? Does it matter if I'm healthy? We need publicly funded research to answer questions like these that are of interest to the public, not only research of interest to private industry. We also need people who have the skills to answer those questions and avoid pitfalls and bias that can plague bad research. Join me today to learn how changes at the National Institutes of Health affect all of us and what we can do!Dr Mary Rice, MD, MPH is a pulmonary and critical care medicine physician and the director of the Center for Climate, Health and the Global Environment at the Harvard TH Chan School of Public Health. She is the chair of the Environmental, Occupational and Population Health Assembly of the American Thoracic Society and leads the environmental health research program of the American Lung Association Lung Health Cohort and is an NIH funded researcher. To DoSpeak up about the value of research- contact your elected officials about the importance of the NIH and publicly funded researchIf you or a loved one suffers from a chronic disease, share how important it is to fund research into disease prevention and treatment. Find the organization that advocates for those with that illness and work with them to raise the issue to decision makers and funders.If you work in research, share your story and help people understand how the scientific method, though not perfect, is one of our best tools in moving human health forwardLearn more about the cuts from a former program officer at the NIH as well as a pediatric pulmonologist that was recorded at the ATS meeting in 2025 for the ATS Breathe Easy podcastIf you work in healthcare, get engaged with your professional societies to advocate for the importance of research.Consider a donation to the American Thoracic Society, which also funds research to help the world breathe-----------------------------------------------------------------------------------------Visit blog post for more information, or go to airhealthourhealth.org.Follow and comment on Facebook page and Instagram. Record a question or comment on the podcast site or send an e-mail via the website. 

I forbindelse med Verdensdagen for psykisk helse tar vi et dypdykk i verktøy som kan styrke vår mentale beredskap. Pia og Silje har også deltatt på kvinnehelseseminar og deler viktige takeaways fra foredragene, blant annet om hvilken rolle bekkenbunnstrening kan spille for seksualfunksjon, lyst, nytelse og orgasme. I tillegg får du høre Pias friske race report fra Hyrox! God lytt!Lenke til NIH sitt kvinnehelseseminar som det refereres til i episoden: Norges idrettshøgskole - YouTubeSjekk ut Siljethorstensen.no for å lære mer om Siljes tjenester, yogakurs og treningsmuligheter. Sjekk ut Piaseeberg.no for å sjekke ut Pias tjenester, kurs og treningsmuligheter. Påmelding og info om den neste treningsreisen vår til Hellas her: Treningsreise med Pia & Silje til Sivota Retreat | Apollo Hosted on Acast. See acast.com/privacy for more information.

This week we review a recent multicenter, randomized trial pitting 2 different immunosuppressive therapeutic approaches against each other. How did a novel approach of everolimus + low dose tacrolimus compare to more standard MMF + standard, higher dose tacrolimus in avoidance of major adverse transplant events or complications? How did this first ever prospective trial in the pediatric heart transplantation world start and how difficult was it to perform in the absence of corporate or NIH support? Why can these data help inform FDA labelling for this novel approach and why is this important? Dr. Kevin Daly of Boston Children's Hospital shares his deep insights into this work this week!DOI: 10.1001/jama.2025.14338

Send us a textUrban A. Kiernan, Ph.D. has over 25 years of industry business and research experience that has spanned from diagnostics, biomarkers, sports antidoping and now into biopharmaceutical discovery.Dr. Kiernan is the Founder, Chairman and CEO of iMetabolic Biopharma Corporation (iMBP), an early stage TechBio company that is developing an innovative AI computational drug discovery technology, as well as an early stage drug pipeline with assets gearing towards the treatment of metabolic, cardiovascular and neuro-degenerative diseases.With one business exit under his belt, he has also been the recipient of almost $5M in NIH awards, holds 12 issued patents, authored ~50 peer reviewed publications and four book chapters.He is a husband and father of three (grandfather of one), as well as is the host of the Decoding Health Podcast. Even though he owns his own drug discovery company, he is an advocate for personal accountability and commitment to health and health span.For fun he holds a 2nd degree black belt in Judo and recently received his black belt in Brazilian Jiu Jitsu.Find Dr. Kiernan at-LK- Urban A. Kiernan, Ph.D.IG- @light_bearerYT- @DecodingHealthPodcasthttps://www.decodinghealthpodcast.com/Find Boundless Body at- myboundlessbody.com Book a session with us here!

Broadcast from KSQD, Santa Cruz on 10-02-2025: Dr. Dawn opens by explaining how blood pressure treatment guidelines have been corrected back to 140/90 after the problematic 2015 SPRINT study temporarily changed recommendations to 120/80. That study used ideal measurement conditions - five minutes of quiet sitting, perfect cuff sizes, compliant patients - creating unrealistic targets that caused elderly patients to faint and break hips. The Veterans Administration and major cardiology organizations now recommend treating to 140/90, with statins only for LDL above 190 or 12% ten-year cardiovascular risk. An emailer asks about claims linking Tylenol to autism. Dr. Dawn thoroughly debunks this, explaining that Swedish studies of 2.5 million children found no association when controlling for sibling comparisons. She notes autism rates remained flat from 1960-1990 despite widespread Tylenol use, then spiked after DSM-4 in 1994 and DSM-5 in 2013 broadened diagnostic criteria. Recall bias skews studies since mothers of autistic children are asked leading questions about past Tylenol use during pregnancy when fever treatment was medically necessary. She discusses RFK Jr.'s mixed positions, comparing him to Isaac Newton who excelled at physics but believed in astrology. While criticizing vaccine misinformation, Dr. Dawn strongly supports RFK's stance on ultra-processed foods. She describes NIH researcher Kevin Hall's studies showing people consume 500 extra calories daily on ultra-processed diets versus whole foods, even when nutrients are matched. The US produces 15,000 calories per person daily, with the food industry engineered to promote overconsumption through hyper-palatable fat-sugar-salt combinations. A caller asks about Healthcare 4.0 plans for biometric tracking bracelets and digital twins. Dr. Dawn discusses privacy concerns around constant health monitoring and data collection, noting that while early disease detection could be valuable, mandatory participation raises serious civil liberties issues. She acknowledges voluntary research projects like the Million Man Study but emphasizes the importance of consent and protection against unauthorized data access by advertisers or government agencies. An emailer shares research on ultrasound brain stimulation helmets as alternatives to surgical electrode implants. Dr. Dawn explains how 256-element phased ultrasonic arrays can target brain regions like the visual cortex with high precision mechanical perturbation, potentially treating Parkinson's, Alzheimer's, and depression without surgery. The technology remains experimental, requiring MRI guidance, but could become portable and dramatically improve quality of life for neurological conditions currently requiring invasive deep brain stimulation. A caller with adrenal cancer asks about fasting-mimicking diets. Dr. Dawn explains that 14-hour fasting before chemotherapy improves outcomes because healthy cells can downshift metabolism while cancer cells cannot. Cancer cells rely only on glycolysis without mitochondrial function, making them vulnerable during fasting states. She recommends chronotherapy - scheduling treatments during fasting periods - and expresses optimism about new cancer therapies like CAR-T cells and CRISPR technologies. An emailer asks about inulin fiber for fatty liver disease. Dr. Dawn explains how this fiber found in chicory, Jerusalem artichokes, and root vegetables stimulates gut bacteria to break down fructose before it reaches the liver, preventing fructose-induced hepatic lipogenesis. Inulin supplementation protects against fatty liver disease, increases antioxidant production, and helps with obesity by reshaping the gut microbiome to better process dietary sugars.

Are you one of the 52 million people in the U.S. who experience chronic pain daily? In It Doesn't Have to Hurt: Your Smart Guide to a Pain-Free Life, the practicing neurosurgeon and CNN's multiple Emmy Award-winning chief medical correspondent debunks the myth that most pain problems can only be fixed with a drug or procedure, and argues that we have agency with how to respond. In conversation with Dr. Anthony Fauci, the former Director of the National Institute of Allergy and Infectious Diseases at the NIH from 1984 to 2022.  This program was held on September 11, 2025. Watch this conversation on YouTube.

Tariffs, drug pricing reform, a government shutdown and a major turnover at one of the world’s largest drugmakers all converged this week, leaving plenty to unpack for the industry as it heads into fall. Greater clarity on President Donald Trump’s tariff and pricing strategies has likely come as something of a relief for those companies operating in the U.S., but that news was tempered by a shutdown of the federal government on Wednesday. Meanwhile, big changes are likely on the way at GSK, whose longtime CEO Emma Walmsley is headed for the exit. In this week’s episode of "The Top Line," we break down some of the biggest stories across Fierce Pharma for the week—which may very well be some of the biggest stories of the year—touching on critical policy updates in the U.S., the furloughing of federal employees at agencies like the FDA and NIH and the imminent departure of GSK’s chief executive. Fierce Life Sciences’ Ben Adams sits down with Fierce Pharma's Fraiser Kansteiner to discuss the latest headlines and go over the key points from each major development that has played out. To learn more about the topics in this episode: FDA avoids the worst amid government shutdown, but new applications put on hold NIH research grinds to a halt as government shuts down Pfizer offers price concessions, $70B US outlay in Trump's 'most favored nation' push Trump's pharma tariffs on hold amid administration's effort to secure pricing concessions, industry investment: Stat GSK's Emma Walmsley to step down as CEO in shock move, giving way to commercial lead Luke Miels See omnystudio.com/listener for privacy information.

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, we discuss: ●How sleep and diet directly influence each other. ●How specific dietary patterns and specific nutrients can improve sleep, and how processed foods may worsen it. ●Ways you can restore the body through REM support for memory and learning. ●How aging and menopause influence sleep ●How light exposure therapy works and how light at night (LAN) can disrupt sleep cycles ●How common disorders like sleep apnea disrupt sleep cycles and how they can be managed effectively. ●How consistent routines, stress reduction, and a healthy environment improve sleep quality. ●If naps are a good idea….and under which circumstances you can maximize their benefits? ●How adequate sleep quality & quantity supports weight regulation, metabolism, and overall heart health. Marie-Pierre St-Onge, Ph.D, CCSH, FAHA  Professor of Nutritional Medicine  Director, Center of Excellence for Sleep & Circadian Research  Division of General Medicine, Department of Medicine  College of Physicians and Surgeons Columbia University Irving Medical Center Address: 622 West- 168 th Street, PH9-103H New York, NY 10032 E-mail: ms2554@cumc.columbia.edu Dr. St-Onge is the founding Director of the Center of Excellence for Sleep Circadian Research at Columbia University Irving Medical Center. The overall focus of her research is the study of the impact of lifestyle, specifically sleep and diet, on cardio-metabolic risk factors. Dr. St-Onge has been NIH-funded since 2008, conducting innovative, cutting-edge clinical research combining her expertise on sleep, nutrition, and energy balance regulation to address questions related to the role of circadian rhythms, including sleep duration and timing as well as meal timing and eating patterns, on cardiometabolic risk. She has strong expertise in the conduct of controlled inpatient and outpatient studies of sleep and dietary manipulations. Dr. St-Onge was Center Director for the American Heart Association funded Go Red for Women Strategically Focused Research Center, aimed at determining the causality of the relation between sleep and cardiovascular disease and the specific role that sleep plays in the health of women throughout the life cycle. She is a pioneer in this field, having chaired the first scientific statements endorsed by the AHA on sleep and cardiometabolic health as well as meal timing and frequency and cardiovascular disease risk prevention. She is the recipient of an NHLBI Outstanding Investigator Award and a standing member of the Human Studies of Diabetes and Obesity Study Section at the NIH.

(0:00) Introducing Cleo Abram (1:12) Why YouTube has become the best platform for creators, techno-optimism at Huge If True (8:35) Astrophysicist Alex Filippenko on the James Webb Space Telescope (23:14) Q&A with Alex Filippenko, Cleo, and Friedberg: The universe, Fermi Paradox, black holes, NIH grants and the “war on science” (37:37) Zipline CEO Keller Rinaudo Cliffton on the future of drone delivery (53:29) Q&A with Keller Rinaudo Cliffton, Cleo, and Friedberg: Instant delivery explosion, competitors, impact on healthcare Thanks to our partners for making this happen! Solana - Solana is the high performance network powering internet capital markets, payments, and crypto applications. Connect with investors, crypto founders, and entrepreneurs at Solana's global flagship event during Abu Dhabi Finance Week & F1: https://solana.com/breakpoint OKX - The new way to build your crypto portfolio and use it in daily life. We call it the new money app. https://www.okx.com/ Google Cloud - The next generation of unicorns is building on Google Cloud's industry-leading, fully integrated AI stack: infrastructure, platform, models, agents, and data. https://cloud.google.com/ IREN - IREN AI Cloud, powered by NVIDIA GPUs, provides the scale, performance, and reliability to accelerate your AI journey. https://iren.com/ Oracle - Step into the future of enterprise productivity at Oracle AI Experience Live. https://www.oracle.com/artificial-intelligence/data-ai-events/ Circle - The America-based company behind USDC — a fully-reserved, enterprise-grade stablecoin at the core of the emerging internet financial system. https://www.circle.com/ BVNK - Building stablecoin-powered financial infrastructure that helps businesses send, store, and spend value instantly, anywhere in the world. https://www.bvnk.com/ Polymarket - https://www.polymarket.com/ Follow Cleo: https://x.com/cleoabram https://www.youtube.com/c/CleoAbram Follow Keller: https://x.com/keller Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg

“Enough is enough.” That's the rallying cry of more than 100 health advocacy groups uniting under the banner of 704 No More™ — a coalition determined to restore local governments' rights over the placement of cell towers and antennas. Why? Because in 1996, Congress quietly passed Section 704 of the Telecom Act, which stripped local communities of the ability to fight these towers on health or environmental grounds. Nearly three decades later, wireless infrastructure has multiplied, exposures have intensified, and communities remain powerless. In this episode of The Healthier Tech Podcast, host R Blank sits down with longtime health advocate Camilla Rees and telecom attorney Scott McCollough, Esq., to uncover: How industry lobbying created Section 704—and why it still protects profits over people The science regulators ignore: decades of Navy, NASA, NIH, and EPA studies showing EMFs disrupt DNA, immunity, and ecosystems Why you can't sue for property loss or illness when a tower goes up near your home The safer alternative: how fiber-to-the-home could cut EMF exposure by hundreds of times while keeping fast connectivity Why the FCC is one of the most captured agencies in Washington—and what it means for your health This episode dives deep into health, rights, and the hidden history of U.S. telecom policy. If you care about your family, your property, or your community, you don't want to miss it. Connect with Camilla Rees & Scott McCollough Website: www.704NoMore.org Facebook: facebook.com/704NoMore Connect with R Blank: For more Healthier Tech Podcast episodes, and to download our Healthier Tech Quick Start Guide, visit https://HealthierTech.co and follow https://instagram.com/healthiertech  Additional Links: EMF Superstore: https://ShieldYourBody.com (save 15% with code “pod”) Digital Wellbeing with a Human Soul: https://Bagby.co (save 15% with code “pod”) Youtube: https://youtube.com/shieldyourbody Instagram: https://www.instagram.com/bagbybrand/  Tiktok: https://www.tiktok.com/@bagby.co Facebook: https://www.facebook.com/shieldyourbody  This episode is brought to you by Shield Your Body—a global leader in EMF protection and digital wellness. Because real wellness means protecting your body, not just optimizing it. If you found this episode eye-opening, leave a review, share it with someone tech-curious, and don't forget to subscribe to Shield Your Body on YouTube for more insights on living healthier with technology.  

(0:00) Introducing Eli Lilly CEO Dave Ricks (1:43) How Eli Lilly discovered the GLP-1 impact on weight loss, counterfeit products from China (7:08) GLP-1 pricing and capital allocation after a breakout pharma product (12:56) Why Biotech VC has plummeted, “patent hacking” in China (15:32) Dave's health regimen: good sleep, movement, healthy diet, social relationships, reading (18:32) Unexpected impacts of GLP-1s, helping with addictions, potential mental health use cases (21:16) Thoughts on RFK Jr, Big Pharma's influence on the media, how AI empowers patients (25:27) Impact of proposed NIH cuts, explaining the “PBM boogeyman”, next major pharma breakthrough Thanks to our partners for making this happen! Solana - Solana is the high performance network powering internet capital markets, payments, and crypto applications. Connect with investors, crypto founders, and entrepreneurs at Solana's global flagship event during Abu Dhabi Finance Week & F1: https://solana.com/breakpoint OKX - The new way to build your crypto portfolio and use it in daily life. We call it the new money app. https://www.okx.com/ Google Cloud - The next generation of unicorns is building on Google Cloud's industry-leading, fully integrated AI stack: infrastructure, platform, models, agents, and data. https://cloud.google.com/ IREN - IREN AI Cloud, powered by NVIDIA GPUs, provides the scale, performance, and reliability to accelerate your AI journey. https://iren.com/ Oracle - Step into the future of enterprise productivity at Oracle AI Experience Live. https://www.oracle.com/artificial-intelligence/data-ai-events/ Circle - The America-based company behind USDC — a fully-reserved, enterprise-grade stablecoin at the core of the emerging internet financial system. https://www.circle.com/ BVNK - Building stablecoin-powered financial infrastructure that helps businesses send, store, and spend value instantly, anywhere in the world. https://www.bvnk.com/ Polymarket: https://www.polymarket.com/ Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg

Preview: Dr. Henry Miller celebrates vaccines for dramatically increasing longevity and eradicating diseases like polio. He notes the success of COVID-19 shots and criticizes the NIH for defunding promising mRNA cancer research. 1919

CBS EYE ON THE WORLD WITH JOHN BATCHELOR 194O LAS VEGAS THE SHOW BEGINS IN THE DOUBTS ABOUT LAS VEGAS...... 9-26-25 FIRST HOUR 9-915 Jeff Bliss reports while Las Vegas is struggling, two planned communities, Cadence and Summerlin, are prospering due to master-planned amenities, strong schools, and feeding Vegas with upper management. 915-930 Jeff Bliss reports while Las Vegas is struggling, two planned communities, Cadence and Summerlin, are prospering due to master-planned amenities, strong schools, and feeding Vegas with upper management. 930-945 Richard Epstein analyzes James Comey's indictment as presidential vengeance using a potentially strong legal case. He argues Trump acts illegally in Venezuela to be feared, benefiting from lack of legal resistance. 945-1000 Richard Epstein analyzes James Comey's indictment as presidential vengeance using a potentially strong legal case. He argues Trump acts illegally in Venezuela to be feared, benefiting from lack of legal resistance. SECOND HOUR 10-1015 Gene Marks reports that massive spending by tech giants on data centers is driving demand for aluminum, steel, and copper, offsetting the softening commercial construction market. 1015-1030 Gene Marks reports that massive spending by tech giants on data centers is driving demand for aluminum, steel, and copper, offsetting the softening commercial construction market. 1030-1045 Bob Zimmerman discusses a brilliant concept by European engineers: "tumbleweed" rovers. These swarm vehicles would roll across Mars, blown by the wind, acting as weather stations. 1045-1100 Bob Zimmerman discusses a brilliant concept by European engineers: "tumbleweed" rovers. These swarm vehicles would roll across Mars, blown by the wind, acting as weather stations. THIRD HOUR 1100-1115 Henry Sokolski discusses the scope of the "Golden Dome" for America, questioning if it should protect space access, LEO, or cis-lunar space. Its potential reorientation to counter Chinese/Russian threats is necessary. 1115-1130 Henry Sokolski discusses the scope of the "Golden Dome" for America, questioning if it should protect space access, LEO, or cis-lunar space. Its potential reorientation to counter Chinese/Russian threats is necessary. 1130-1145 Brandon Weichert discusses AI growth driven by massive data centers, facing bottlenecks in land, energy, and fresh water access. The Chips Act struggles; the economic boom risks are significant if high-end chip access is lost. 1145-1200 Preview: Dr. Henry Miller celebrates vaccines for dramatically increasing longevity and eradicating diseases like polio. He notes the success of COVID-19 shots and criticizes the NIH for defunding promising mRNA cancer research. FOURTH HOUR 12-1215 Preview: Conrad Black endorses Tony Blair for leading the Gaza International Transitional Authority under a proposed Trump peace plan. Blair is viewed as fair and capable of removing Hamas influence. 1215-1230 Preview: Lorenzo Fiori reports that Milan, the current center of worldwide fashion, shows no recession signs. High-end spending, luxury shopping, and vibrant nightlife suggest people have money to spend. 1230-1245 Preview: Juliana Geran Pilon discusses how Founding Fathers viewed the Hebrew nation as an ideal for America, rooted in a divine creator. She warns that moral relativism and secularism now assault this core foundation. 1245-100 AM Preview: Juliana Geran Pilon discusses how Founding Fathers viewed the Hebrew nation as an ideal for America, rooted in a divine creator. She warns that moral relativism and secularism now assault this core foundation.

“This is Ground Zero for Agenda 2030 across the Globe. What is here Epitomizes what ALL Farmers are Facing, including the Highest Risk of Mankind's Food Security and Natural Solutions to Heal being Eradicated from God's Creation” Mere hours from the peaceful, 35-yr old multi-generational farm in British Columbia, a CHILD IS REPORTED MISSING and a community responds… Yet instead of mounting area-wide search efforts for the child… An estimated 140 RCMP vehicles, with an estimated 200+ armed RCMP agents, their Helicopters, Surveillance Units, Drones, a Mobile Command Unit including the RCMP Tactical Team (Emergency Response Unit deployed in acts of terrorism) convoyed 3 hours, descending upon Universal Ostrich Farms. What mission is more important than searching for a missing 5yr old boy? What warrants this over investigating and dismantling terrorist networks? Or stopping the flow of deadly fentanyl, drug trafficking or human smugglers?  Even investigating crimes against humanity, or... Hunting down sexual predators? (By their very actions, words and deeds, to these members of the RCMP, it's more important to support a W.H.O. proclamation pushed by Canada's deep state and kill these birds...)  Along a scenic highway inside the Rocky Mountain interior this week, dozens of law enforcement began terrorizing the Grandmother, her daughter Katie Pasitney, and co-owner David Belinski.   The government agents swarmed the farm, locking down airspace and planting themselves firmly on private property setting up to eviscerate 400 healthy ostriches with 230 healthy days of herd immunity.  The antibodies produced by the eggs of these very ostriches have been clinically proven across numerous studies from the USA to Kyoto University in Japan, to prevent or heal humans from various strains of flu, from COVID itself, plus provide a natural diet alternative to Big Pharma's Ozempic...and perhaps might potentially heal cancer. 

In the past few weeks, we've done several episodes on obesity, GLP-1 drugs, and nutrition science. What we haven't talked about as much is the politics of food. And today's guests say: If you really want to understand why Americans are so unhealthy, you have to see that the problem is not just our willpower, and it's not just our food itself. It's our food policies. Kevin Hall was a former top nutrition researcher at the NIH who retired after accusing RFK Jr. and the Department of Health and Human Services of censoring a report that questioned their description of ultra-processed foods. Julia Belluz is a longtime nutrition and health journalist. Together, they've written a new book, 'Food Intelligence: The Science of How Food Both Nourishes and Harms Us.' If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com. Host: Derek Thompson Guests: Julia Belluz and Kevin Hall Producer: Devon Baroldi Learn more about your ad choices. Visit podcastchoices.com/adchoices

Friday, September 26, 2025. Week 39.   In this episode of Syngap10, we continue the conversation from Episode 183, sharing the latest milestones and moments with our SYNGAP1 community.   DSC has announced! DSC (part of RDCRN, part of NCATS, part of NIH) also announced and continues to raise profile of SYNGAP1 Related Disorders (SRD) Key post https://www.linkedin.com/posts/curesyngap1_86-million-nih-grant-renews-support-for-activity-7373870761230589952-aV1M #RDCRN List with #DSC https://ncats.nih.gov/research/research-activities/rdcrn/consortia   In addition to that, the DSC was formally announced, and will result in five years of SYNGAP1 securing a spot on the map.  This was because of an SRF grant years ago!  Grant https://curesyngap1.org/blog/syngap-research-fund-announces-308-000-multidisciplinary-biomarker-grant-to-boston-childrens-hospital/   Pubmed is at 44! (+2 v ‘23, -10 v ‘24, 2nd place) https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2025-2025&timeline=expanded&sort=date&sort_order=asc   Cell Paper on AAV in Mice: https://www.linkedin.com/posts/boaz-levi-07387741_aav-delivery-of-full-length-syngap1-rescues-activity-7376306391537532928-iT9u    Last week was a CB Conf in Nashville, attended by KAH and VA, thank you to both.  KAH in Staff yesterday, the hardest thing is not seeing Joey.  ☹️  Thanks to MS for going too. MS https://www.linkedin.com/posts/melissasmith1_raredisease-patientadvocacy-syngap1-activity-7374408667091333120-Udp0/ KAH https://www.linkedin.com/posts/kathryn-syngap-research-fund_the-combinedbrain-conference-in-nashville-activity-7374639535021928448-gWB4    Two big upcoming events: Scramble in SC on October 4th https://www.linkedin.com/posts/julie-miles-4294322ba_scramble-for-syngap-activity-7370558331611971585-iw0A    CURE SYNGAP1 Conference 2025 in Atlanta https://curesyngap1.org/events/conferences/cure-syngap1-conference-2025-hosted-by-srf/   SOCIAL MATTERS - 4,371 LinkedIn.  https://www.linkedin.com/company/curesyngap1/  - 1,440 YouTube.  https://www.youtube.com/@CureSYNGAP1    - 11,292 Twitter https://twitter.com/cureSYNGAP1  - 45k Insta https://www.instagram.com/curesyngap1/    COMPANIES WITH NAMED ASSETS FOR SYNGAP1 $CAMP $3.00 at close on 9/23   Episode 184 of #Syngap10 #CureSYNGAP1 #Advocate #PatientAdvocacy #UnmetNeed #SYNGAP1 #SynGAP #SynGAProMMiS

Learn how to prepare for a government shutdown and where to put $600 a month after building your emergency fund. What happens in a federal government shutdown? Where should you put $600/month after funding an emergency cushion? Hosts Sean Pyles and Elizabeth Ayoola discuss the looming shutdown before answering a listener's question about where to allocate their extra income. They begin with senior news writer Anna Helhoski, breaking down how a lapse in government funding could affect benefits, travel, parks, mail, and taxes, and how to keep your own plan steady. Then, Elizabeth and Sean answer a listener's question about how to think about allocating $600/month. They discuss automating IRA/solo 401(k)/SEP IRA contributions, using diversified index or mutual funds and a taxable brokerage, balancing a home down payment with retirement via time horizons and DTI/credit score, and what to look for in funds. They also explore how habit-building and automation can help you grow retirement savings while still working toward a down payment. Get matched with a financial advisor for free: https://www.nerdwallet.com/l/advisor-match-financial  Are you on track to save enough for retirement? Use NerdWallet's free calculator to check your progress, see how much retirement income you'll have and estimate how much more you should save: https://www.nerdwallet.com/calculator/retirement-calculator  Want us to review your budget? Fill out this form — completely anonymously if you want — and we might feature your budget in a future segment! https://docs.google.com/forms/d/e/1FAIpQLScK53yAufsc4v5UpghhVfxtk2MoyooHzlSIRBnRxUPl3hKBig/viewform?usp=header In their conversation, the Nerds discuss: Social Security during shutdown, TSA delays shutdown, Medicare during shutdown, Medicaid during shutdown, WIC benefits shutdown, IRS refund delays, FAFSA processing delay, federal employees furlough, furloughed vs essential workers, continuing resolution, national park closures shutdown, food safety inspections shutdown, EPA inspections shutdown, FDA inspections shutdown, NIH grants shutdown, unemployment benefits shutdown, debt-to-income ratio mortgage, mortgage approval process, credit score mortgage requirement, down payment savings strategy, closing costs when buying a home, emergency savings for home repairs, retirement calculator, 15 percent retirement savings rule, ETF vs mutual fund, S&P 500 index fund, expense ratio explained, index fund performance history, index fund tracking error, taxable brokerage account basics, diversification in investing, automate retirement contributions, solo 401k contribution limit, and SEP IRA contribution limit. To send the Nerds your money questions, call or text the Nerd hotline at 901-730-6373 or email podcast@nerdwallet.com. Like what you hear? Please leave us a review and tell a friend. Learn more about your ad choices. Visit megaphone.fm/adchoices

00:48 New insights into tick-borne encephalitisResearchers have identified a key protein that helps tick-borne encephalitis virus enter the brain. In rare cases an infection can lead to serious neurological symptoms, but little was known about how the virus interacts with human cells. Now, a team show that a protein found on the outside of cells plays an important role in infection. In mouse experiments, they show that blocking the ability of the virus to bind to this protein protected the mice from disease. Currently no treatments exist, but the team hopes that this research will ultimately lead to a viable drug for this disease.Research Article: Mittler et al.08:47 Research HighlightsThe squirming robot that speeds up the insertion of an emergency breathing tube — plus, the 10,000-year-old remains that could be the oldest intentionally preserved mummiesResearch Highlight: Soft robot steers itself down the human airwayResearch Highlight: Smoke-dried mummies pre-date Egypt's embalmed bodies11:21 How might cancelled NIH grants affect the future of US science?To assess the potential impact of cuts to funding by the Trump administration, Nature trained a machine-learning bot to try and reproduce the NIH's method of cancelling grants and applied it to science that was successfully funded around ten years ago. This thought experiment shows that highly impactful science and medical research might have been at risk had a similar process been followed a decade ago, revealing the potentially broad-reaching consequences of these actions today.Nature Index: What research might be lost after the NIH's cuts? Nature trained a bot to find outNews: Are the Trump team's actions affecting your research? How to contact Nature20:54 Briefing ChatWhat researchers understand about chatbot-induced psychosis, and the AI designed viruses capable of killing E. coli bacteria.Nature: Can AI chatbots trigger psychosis? What the science saysNature: World's first AI-designed viruses a step towards AI-generated lifeSubscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.

Setting: President Trump held a press conference after attending Charlie Kirk’s funeral, teasing it as a “major announcement” on autism and public health. Main Claim: Trump and RFK Jr. asserted that acetaminophen (Tylenol) use during pregnancy may be associated with an increased risk of autism in children. Trump directly warned against taking Tylenol while pregnant, except in extreme cases of high fever. Autism Statistics (as presented by Trump): Historical rates cited: 1 in 20,000 → 1 in 10,000 → 1 in 31 overall today, and as high as 1 in 12 among boys in some regions (e.g., California). He described this increase as “artificial” and linked it to medication and vaccines. Specific Policy Steps Announced: FDA to issue warnings and update labeling for acetaminophen, cautioning its use during pregnancy. NIH, FDA, CDC, and CMS to coordinate a new effort investigating potential environmental, pharmaceutical, and vaccine links to autism. New grant funding (13 awards) through NIH’s Autism Data Science Initiatives. Other Health Proposals Trump Raised: Vaccines: suggested spacing them out, avoiding certain ingredients (mercury, aluminum), giving MMR separately, and delaying hepatitis B vaccination until age 12. Treatment: referenced new findings suggesting folate deficiency in children may contribute to autism, with therapies under research. RFK Jr.’s Role: He emphasized that past autism research was too focused on genetics and ignored environmental/toxic exposures. Supported Trump’s push to investigate acetaminophen, vaccines, and other potential causes. Announced NIH/FDA would pursue depoliticized research, new label warnings, and public education campaigns. Please Hit Subscribe to this podcast Right Now. Also Please Subscribe to the The Ben Ferguson Show Podcast and Verdict with Ted Cruz Wherever You get You're Podcasts. And don't forget to follow the show on Social Media so you never miss a moment! Thanks for Listening X: https://x.com/benfergusonshowYouTube: https://www.youtube.com/@VerdictwithTedCruzSee omnystudio.com/listener for privacy information.

Dr. Jay Bhattacharya is one of the country's top medical experts and a 24-year professor of medicine at Stanford. After being censored and deplatformed during COVID for his role in opposing harsh lockdowns, he was appointed Director of the National Institutes of Health by President Trump in 2025.a16z General Partners Erik Torenberg, Vineeta Agarwala, and Jorge Conde join Dr. Bhattacharya to discuss the administration's role in tackling the autism crisis, how to restore public trust in health authorities, how to make the NIH more dynamic and efficient, and how to streamline publishing and restore academic freedom.Timecodes: 0:00 Introduction1:30 Autism Initiative & New Research2:45 Drug Discoveries: Leucovorin & Tylenol Caution4:35 Preterm Birth & Broader Health Initiatives5:45 The Replication Crisis in Science8:50 Reforming NIH Funding & Scientific Culture14:00 Allocation vs. Execution at NIH17:30 Political & Scientific Decision-Making22:30 Addressing Life Expectancy & Chronic Disease27:00 Supporting Early Career Investigators34:50 Academic Freedom & Open Science37:30 Rebuilding Public Trust in Public Health41:00 Communicating Science Amid Uncertainty47:50 NIH Priorities: Nutrition, Chronic Disease, AI50:00 The Future of AI in Science & Medicine53:30 Advice for Rising Scientists55:00 The Role and Limits of AI in Science Resources:Find Dr. Bhattacharya on X: https://x.com/DrJBhattacharya and https://x.com/NIHDirector_JayFind Erik on X: https://x.com/eriktorenbergFind Jorge on X: https://x.com/JorgeCondeBioFind Vineeta on X: https://x.com/vintweetaLearn more about the NIH: https://www.nih.gov/ Stay Updated:Find a16z on XFind a16z on LinkedInListen to the a16z Podcast on SpotifyListen to the a16z Podcast on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.